Jelić-Ivanović, Zorana

Link to this page

Authority KeyName Variants
orcid::0000-0002-3791-1743
  • Jelić-Ivanović, Zorana (174)
Projects

Author's Bibliography

Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?

Vladimirov, Sandra; Gojković, Tamara; Zeljković, Aleksandra; Jelić-Ivanović, Zorana; Zeljković, Dejan; Antonić, Tamara; Trifunović, Bratislav; Spasojević-Kalimanovska, Vesna

(Elsevier Inc., 2022)

TY  - JOUR
AU  - Vladimirov, Sandra
AU  - Gojković, Tamara
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Zeljković, Dejan
AU  - Antonić, Tamara
AU  - Trifunović, Bratislav
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4178
AB  - Colorectal cancer (CRC) is a highly prevalent malignancy. Previous studies suggested that cholesterol might play a signficant role in malignant transformation and proliferation. Non-cholesterol sterols (NCS), which are transported by serum lipoproteins alongside cholesterol, are regarded as cholesterol synthesis and absorption markers. Quantification of NCS in serum and HDL fraction (NCSHDL), could provide a better insight into the cholesterol metabolism. The aim of this study was to examine the status of cholesterol synthesis and cholesterol absorption markers in serum and HDL fraction and explore their interrelation in CRC patients. Current study was designed as observational, case-control study. The study included 73 CRC patients and 95 healthy subjects. NCS and NCSHDL concentrations were determined by HPLC-MS/MS. Based on NCS and NCSHDL concentrations, different cholesterol homeostasis indices were calculated. Patients had significantly lower NCS (P<0.001) and NCSHDL concentrations (P<0.001 for desmosterolHDL; P<0.05 for lathosterolHDL, P=0.001 for campesterolHDL, P<0.001 for β-sitosterolHDL). NCSHDL/NCS (P<0.005 for desmosterolHDL/desmosterol; P<0.05 for lathosterolHDL/lathosterol; P<0.001 for both β-sitosterolHDL/β-sitosterol and campesterolHDL/campesterol) and synthesis to absorption ratio (CSI/CAI) (P<0.005) were increased in CRC patients. Additionally, low serum concentrations of desmosterol (P<0.001; OR=0.329; 95%CI (0.199–0.542)) and campesterol (P<0.001; OR=0.540; 95%CI (0.424–0.687)) were independent predictors of CRC presence. Our data suggest that cholesterol homeostasis in CRC is shifted towards increased synthesis. Relative abundance of NCS in HDL particles is increased, suggesting the possible overproduction of cholesterol precursors in peripheral tissues.
PB  - Elsevier Inc.
T2  - Biochemical Pharmacology
T1  - Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?
VL  - 196
DO  - 10.1016/j.bcp.2021.114595
ER  - 
@article{
author = "Vladimirov, Sandra and Gojković, Tamara and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Zeljković, Dejan and Antonić, Tamara and Trifunović, Bratislav and Spasojević-Kalimanovska, Vesna",
year = "2022",
abstract = "Colorectal cancer (CRC) is a highly prevalent malignancy. Previous studies suggested that cholesterol might play a signficant role in malignant transformation and proliferation. Non-cholesterol sterols (NCS), which are transported by serum lipoproteins alongside cholesterol, are regarded as cholesterol synthesis and absorption markers. Quantification of NCS in serum and HDL fraction (NCSHDL), could provide a better insight into the cholesterol metabolism. The aim of this study was to examine the status of cholesterol synthesis and cholesterol absorption markers in serum and HDL fraction and explore their interrelation in CRC patients. Current study was designed as observational, case-control study. The study included 73 CRC patients and 95 healthy subjects. NCS and NCSHDL concentrations were determined by HPLC-MS/MS. Based on NCS and NCSHDL concentrations, different cholesterol homeostasis indices were calculated. Patients had significantly lower NCS (P<0.001) and NCSHDL concentrations (P<0.001 for desmosterolHDL; P<0.05 for lathosterolHDL, P=0.001 for campesterolHDL, P<0.001 for β-sitosterolHDL). NCSHDL/NCS (P<0.005 for desmosterolHDL/desmosterol; P<0.05 for lathosterolHDL/lathosterol; P<0.001 for both β-sitosterolHDL/β-sitosterol and campesterolHDL/campesterol) and synthesis to absorption ratio (CSI/CAI) (P<0.005) were increased in CRC patients. Additionally, low serum concentrations of desmosterol (P<0.001; OR=0.329; 95%CI (0.199–0.542)) and campesterol (P<0.001; OR=0.540; 95%CI (0.424–0.687)) were independent predictors of CRC presence. Our data suggest that cholesterol homeostasis in CRC is shifted towards increased synthesis. Relative abundance of NCS in HDL particles is increased, suggesting the possible overproduction of cholesterol precursors in peripheral tissues.",
publisher = "Elsevier Inc.",
journal = "Biochemical Pharmacology",
title = "Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?",
volume = "196",
doi = "10.1016/j.bcp.2021.114595"
}
Vladimirov, S., Gojković, T., Zeljković, A., Jelić-Ivanović, Z., Zeljković, D., Antonić, T., Trifunović, B.,& Spasojević-Kalimanovska, V.. (2022). Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?. in Biochemical Pharmacology
Elsevier Inc.., 196.
https://doi.org/10.1016/j.bcp.2021.114595
Vladimirov S, Gojković T, Zeljković A, Jelić-Ivanović Z, Zeljković D, Antonić T, Trifunović B, Spasojević-Kalimanovska V. Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?. in Biochemical Pharmacology. 2022;196.
doi:10.1016/j.bcp.2021.114595 .
Vladimirov, Sandra, Gojković, Tamara, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Zeljković, Dejan, Antonić, Tamara, Trifunović, Bratislav, Spasojević-Kalimanovska, Vesna, "Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?" in Biochemical Pharmacology, 196 (2022),
https://doi.org/10.1016/j.bcp.2021.114595 . .
1
11
3
10

Indirect reference intervals for haematological parameters in capillary blood of pre-school children

Zeljković, Aleksandra; Balog, Zsófia Csuzd; Dukai, Eva; Vekić, Jelena; Jelić-Ivanović, Zorana; Spasojević-Kalimanovska, Vesna

(Zagreb : Hrvatsko drustvo medicinskih biokemičara, 2021)

TY  - JOUR
AU  - Zeljković, Aleksandra
AU  - Balog, Zsófia Csuzd
AU  - Dukai, Eva
AU  - Vekić, Jelena
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3802
AB  - Introduction: Indirect estimation of reference intervals (RIs) is straightforward and inexpensive procedure for determination of intra-laboratory RIs. We applied the indirect approach to assess RIs for haematological parameters in capillary blood of pre-school children, using results stored in our laboratory database. Materials and methods: We extracted data from laboratory information system, for the results obtained by automatic haematology analyser in capillary blood of 154 boys and 146 girls during pre-school medical examination. Data distribution was tested, and logarithmic transformation was applied if needed. Reference intervals were calculated by the nonparametric percentile method. Results: Reference intervals were calculated for: RBC count (4.2-5.4 x1012/L), haemoglobin (114-146 g/L), MCH (25.0-29.4 pg), MCHC (321-368 g/L), RDW-SD (36.1-43.5 fL), WBC count (4.5-12.3 x109/L), neutrophils count (1.7-6.9 x109/L) and percentage (29.0-69.0%), lymphocytes count (1.6-4.4 x109/L) and percentage (21.9-60.7%), PLT (165-459 x109/L), MPV (8.1-11.4 fL) and PDW (9.2-14.4%). Gender specific RIs were calculated for mo-nocytes count (male (M): 0.2-1.6 x109/L; female (F): 0.1-1.4 x109/L) and percentage (M: 2.5-18.3%; F: 1.8-16.7%), haematocrit (M: 0.34-0.42 L/L; F: 0.34-0.43 L/L), MCV (M: 73.4-84.6 fL; F: 75.5-84.2 fL) and RDW (M: 12.1-14.3%; F: 11.7-13.9%), due to observed gender differences in these parameters (P = 0.031, 0.028, 0.020, 0.012 and 0.001; respectively). Estimated RIs markedly varied from the literature based RIs that are used in the labora-tory. Conclusions: Indirect method employed in this study enables straightforward assessment of RIs in pre-school children. Herein derived RIs differed from the literature-based ones, indicating the need for intra-laboratory determination of RIs for specific populations and sample types.
PB  - Zagreb : Hrvatsko drustvo medicinskih biokemičara
T2  - Biochemia Medica
T1  - Indirect reference intervals for haematological parameters in capillary blood of pre-school children
VL  - 31
IS  - 1
SP  - 1
EP  - 9
DO  - 10.11613/BM.2021.010709
ER  - 
@article{
author = "Zeljković, Aleksandra and Balog, Zsófia Csuzd and Dukai, Eva and Vekić, Jelena and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna",
year = "2021",
abstract = "Introduction: Indirect estimation of reference intervals (RIs) is straightforward and inexpensive procedure for determination of intra-laboratory RIs. We applied the indirect approach to assess RIs for haematological parameters in capillary blood of pre-school children, using results stored in our laboratory database. Materials and methods: We extracted data from laboratory information system, for the results obtained by automatic haematology analyser in capillary blood of 154 boys and 146 girls during pre-school medical examination. Data distribution was tested, and logarithmic transformation was applied if needed. Reference intervals were calculated by the nonparametric percentile method. Results: Reference intervals were calculated for: RBC count (4.2-5.4 x1012/L), haemoglobin (114-146 g/L), MCH (25.0-29.4 pg), MCHC (321-368 g/L), RDW-SD (36.1-43.5 fL), WBC count (4.5-12.3 x109/L), neutrophils count (1.7-6.9 x109/L) and percentage (29.0-69.0%), lymphocytes count (1.6-4.4 x109/L) and percentage (21.9-60.7%), PLT (165-459 x109/L), MPV (8.1-11.4 fL) and PDW (9.2-14.4%). Gender specific RIs were calculated for mo-nocytes count (male (M): 0.2-1.6 x109/L; female (F): 0.1-1.4 x109/L) and percentage (M: 2.5-18.3%; F: 1.8-16.7%), haematocrit (M: 0.34-0.42 L/L; F: 0.34-0.43 L/L), MCV (M: 73.4-84.6 fL; F: 75.5-84.2 fL) and RDW (M: 12.1-14.3%; F: 11.7-13.9%), due to observed gender differences in these parameters (P = 0.031, 0.028, 0.020, 0.012 and 0.001; respectively). Estimated RIs markedly varied from the literature based RIs that are used in the labora-tory. Conclusions: Indirect method employed in this study enables straightforward assessment of RIs in pre-school children. Herein derived RIs differed from the literature-based ones, indicating the need for intra-laboratory determination of RIs for specific populations and sample types.",
publisher = "Zagreb : Hrvatsko drustvo medicinskih biokemičara",
journal = "Biochemia Medica",
title = "Indirect reference intervals for haematological parameters in capillary blood of pre-school children",
volume = "31",
number = "1",
pages = "1-9",
doi = "10.11613/BM.2021.010709"
}
Zeljković, A., Balog, Z. C., Dukai, E., Vekić, J., Jelić-Ivanović, Z.,& Spasojević-Kalimanovska, V.. (2021). Indirect reference intervals for haematological parameters in capillary blood of pre-school children. in Biochemia Medica
Zagreb : Hrvatsko drustvo medicinskih biokemičara., 31(1), 1-9.
https://doi.org/10.11613/BM.2021.010709
Zeljković A, Balog ZC, Dukai E, Vekić J, Jelić-Ivanović Z, Spasojević-Kalimanovska V. Indirect reference intervals for haematological parameters in capillary blood of pre-school children. in Biochemia Medica. 2021;31(1):1-9.
doi:10.11613/BM.2021.010709 .
Zeljković, Aleksandra, Balog, Zsófia Csuzd, Dukai, Eva, Vekić, Jelena, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, "Indirect reference intervals for haematological parameters in capillary blood of pre-school children" in Biochemia Medica, 31, no. 1 (2021):1-9,
https://doi.org/10.11613/BM.2021.010709 . .
6
6

Increased oxidized high-density lipoprotein/ high-density lipoprotein-cholesterol ratio as a potential indicator of disturbed metabolic health in overweight and obese individuals

Janać, Jelena; Zeljković, Aleksandra; Jelić-Ivanović, Zorana; Dimitrijević-Srećković, Vesna; Vekić, Jelena; Miljković, Milica; Stefanović, Aleksandra; Kotur-Stevuljević, Jelena; Ivanišević, Jasmina; Spasojević-Kalimanovska, Vesna

(Oxford University Press, 2020)

TY  - JOUR
AU  - Janać, Jelena
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Dimitrijević-Srećković, Vesna
AU  - Vekić, Jelena
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Kotur-Stevuljević, Jelena
AU  - Ivanišević, Jasmina
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3803
AB  - Background: We evaluated the qualitative characteristics of high-density lipoprotein (HDL) particles in metabolically healthy and unhealthy overweight and obese subjects. Methods: The study involved 115 subject individuals classified as metabolically healthy and unhealthy, as in overweight and obese groups. Commercial enzyme-linked immunosorbent assay (ELISA) kits were used to measure oxidized HDL (OxHDL) and serum amyloid A (SAA) concentrations. Lipoprotein subfractions were separated using nondenaturing gradient gel electrophoresis. Results: An independent association was shown between increased OxHDL/HDL-cholesterol ratio and the occurrence of metabolically unhealthy phenotype in the overweight and obese groups. The OxHDL/HDL-cholesterol ratio showed excellent and acceptable diagnostic accuracy in determination of metabolic health phenotypes (overweight group, AUC = 0.881; obese group, AUC = 0.765). Accumulation of smaller HDL particles in metabolically unhealthy subjects was verified by lipoprotein subfraction analysis. SAA concentrations did not differ significantly between phenotypes. Conclusions: Increased OxHDL/HDL-cholesterol ratio may be a potential indicator of disturbed metabolic health in overweight and obese individuals.
PB  - Oxford University Press
T2  - Lab Medicine
T1  - Increased oxidized high-density lipoprotein/ high-density lipoprotein-cholesterol ratio as a potential indicator of disturbed metabolic health in overweight and obese individuals
VL  - 51
IS  - 1
SP  - 24
EP  - 33
DO  - 10.1093/labmed/lmz017
ER  - 
@article{
author = "Janać, Jelena and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Dimitrijević-Srećković, Vesna and Vekić, Jelena and Miljković, Milica and Stefanović, Aleksandra and Kotur-Stevuljević, Jelena and Ivanišević, Jasmina and Spasojević-Kalimanovska, Vesna",
year = "2020",
abstract = "Background: We evaluated the qualitative characteristics of high-density lipoprotein (HDL) particles in metabolically healthy and unhealthy overweight and obese subjects. Methods: The study involved 115 subject individuals classified as metabolically healthy and unhealthy, as in overweight and obese groups. Commercial enzyme-linked immunosorbent assay (ELISA) kits were used to measure oxidized HDL (OxHDL) and serum amyloid A (SAA) concentrations. Lipoprotein subfractions were separated using nondenaturing gradient gel electrophoresis. Results: An independent association was shown between increased OxHDL/HDL-cholesterol ratio and the occurrence of metabolically unhealthy phenotype in the overweight and obese groups. The OxHDL/HDL-cholesterol ratio showed excellent and acceptable diagnostic accuracy in determination of metabolic health phenotypes (overweight group, AUC = 0.881; obese group, AUC = 0.765). Accumulation of smaller HDL particles in metabolically unhealthy subjects was verified by lipoprotein subfraction analysis. SAA concentrations did not differ significantly between phenotypes. Conclusions: Increased OxHDL/HDL-cholesterol ratio may be a potential indicator of disturbed metabolic health in overweight and obese individuals.",
publisher = "Oxford University Press",
journal = "Lab Medicine",
title = "Increased oxidized high-density lipoprotein/ high-density lipoprotein-cholesterol ratio as a potential indicator of disturbed metabolic health in overweight and obese individuals",
volume = "51",
number = "1",
pages = "24-33",
doi = "10.1093/labmed/lmz017"
}
Janać, J., Zeljković, A., Jelić-Ivanović, Z., Dimitrijević-Srećković, V., Vekić, J., Miljković, M., Stefanović, A., Kotur-Stevuljević, J., Ivanišević, J.,& Spasojević-Kalimanovska, V.. (2020). Increased oxidized high-density lipoprotein/ high-density lipoprotein-cholesterol ratio as a potential indicator of disturbed metabolic health in overweight and obese individuals. in Lab Medicine
Oxford University Press., 51(1), 24-33.
https://doi.org/10.1093/labmed/lmz017
Janać J, Zeljković A, Jelić-Ivanović Z, Dimitrijević-Srećković V, Vekić J, Miljković M, Stefanović A, Kotur-Stevuljević J, Ivanišević J, Spasojević-Kalimanovska V. Increased oxidized high-density lipoprotein/ high-density lipoprotein-cholesterol ratio as a potential indicator of disturbed metabolic health in overweight and obese individuals. in Lab Medicine. 2020;51(1):24-33.
doi:10.1093/labmed/lmz017 .
Janać, Jelena, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Dimitrijević-Srećković, Vesna, Vekić, Jelena, Miljković, Milica, Stefanović, Aleksandra, Kotur-Stevuljević, Jelena, Ivanišević, Jasmina, Spasojević-Kalimanovska, Vesna, "Increased oxidized high-density lipoprotein/ high-density lipoprotein-cholesterol ratio as a potential indicator of disturbed metabolic health in overweight and obese individuals" in Lab Medicine, 51, no. 1 (2020):24-33,
https://doi.org/10.1093/labmed/lmz017 . .
1
7
2
7

Paraoxonase 1 and atherosclerosis-related diseases

Kotur-Stevuljević, Jelena; Vekić, Jelena; Stefanović, Aleksandra; Zeljković, Aleksandra; Ninić, Ana; Ivanišević, Jasmina; Miljković, Milica; Sopić, Miron; Munjas, Jelena; Mihajlović, Marija; Spasić, Slavica; Jelić-Ivanović, Zorana; Spasojević-Kalimanovska, Vesna

(Blackwell Publishing Inc., 2020)

TY  - JOUR
AU  - Kotur-Stevuljević, Jelena
AU  - Vekić, Jelena
AU  - Stefanović, Aleksandra
AU  - Zeljković, Aleksandra
AU  - Ninić, Ana
AU  - Ivanišević, Jasmina
AU  - Miljković, Milica
AU  - Sopić, Miron
AU  - Munjas, Jelena
AU  - Mihajlović, Marija
AU  - Spasić, Slavica
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3615
AB  - A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high-density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti-inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis-related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end-stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features. © 2019 International Union of Biochemistry and Molecular Biology
PB  - Blackwell Publishing Inc.
T2  - BioFactors
T1  - Paraoxonase 1 and atherosclerosis-related diseases
VL  - 46
IS  - 2
SP  - 193
EP  - 205
DO  - 10.1002/biof.1549
ER  - 
@article{
author = "Kotur-Stevuljević, Jelena and Vekić, Jelena and Stefanović, Aleksandra and Zeljković, Aleksandra and Ninić, Ana and Ivanišević, Jasmina and Miljković, Milica and Sopić, Miron and Munjas, Jelena and Mihajlović, Marija and Spasić, Slavica and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna",
year = "2020",
abstract = "A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high-density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti-inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis-related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end-stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features. © 2019 International Union of Biochemistry and Molecular Biology",
publisher = "Blackwell Publishing Inc.",
journal = "BioFactors",
title = "Paraoxonase 1 and atherosclerosis-related diseases",
volume = "46",
number = "2",
pages = "193-205",
doi = "10.1002/biof.1549"
}
Kotur-Stevuljević, J., Vekić, J., Stefanović, A., Zeljković, A., Ninić, A., Ivanišević, J., Miljković, M., Sopić, M., Munjas, J., Mihajlović, M., Spasić, S., Jelić-Ivanović, Z.,& Spasojević-Kalimanovska, V.. (2020). Paraoxonase 1 and atherosclerosis-related diseases. in BioFactors
Blackwell Publishing Inc.., 46(2), 193-205.
https://doi.org/10.1002/biof.1549
Kotur-Stevuljević J, Vekić J, Stefanović A, Zeljković A, Ninić A, Ivanišević J, Miljković M, Sopić M, Munjas J, Mihajlović M, Spasić S, Jelić-Ivanović Z, Spasojević-Kalimanovska V. Paraoxonase 1 and atherosclerosis-related diseases. in BioFactors. 2020;46(2):193-205.
doi:10.1002/biof.1549 .
Kotur-Stevuljević, Jelena, Vekić, Jelena, Stefanović, Aleksandra, Zeljković, Aleksandra, Ninić, Ana, Ivanišević, Jasmina, Miljković, Milica, Sopić, Miron, Munjas, Jelena, Mihajlović, Marija, Spasić, Slavica, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, "Paraoxonase 1 and atherosclerosis-related diseases" in BioFactors, 46, no. 2 (2020):193-205,
https://doi.org/10.1002/biof.1549 . .
1
50
21
45

Determination of non-cholesterol sterols in serum and HDL fraction by LC/MS-ms: Significance of matrix-related interferences

Vladimirov, Sandra; Gojković, Tamara; Zeljković, Aleksandra; Jelić-Ivanović, Zorana; Spasojević-Kalimanovska, Vesna

(Belgrade : Society of Medical Biochemists of Serbia, 2020)

TY  - JOUR
AU  - Vladimirov, Sandra
AU  - Gojković, Tamara
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3653
AB  - Background:Non-cholesterol  sterols  (NCS)  are  promising biomarkers for estimation of cholesterol homeostasis properties.  In  addition,  determination  of  NCS  in  high-density lipoprotein (HDL) fraction (HDL-NCS) could provide information on cholesterol efflux. However, matrix effects interfere in liquid chromatography–mass spectrometry (LC-MS)analysis  of  NCS,  thereby  impairing  the  method  sensitivity.The aims of this study were development, optimization and validation  of  LC-MS  method  for  quantification  of  NCS  in serum  and  HDL-NCS.  Additionally,  matrix  effect  interfer-ences  and  methods  application  in  individual  serum  samples were examined.Methods:HDL precipitating reagent was used for HDL isolation. Matrix effect was examined by comparing different surrogates  by  simple  regression  analysis.  Validation  was conducted according to the FDA-ICH guideline. 20 healthy volunteers were recruited for testing of method application.Results:The  observed  matrix  effect  was  30%,  and  matrix comparison  showed  that  cholesterol  was  the  dominant contributor  to  the  matrix  effect.  Cholesterol  concentration was  adjusted  by  construction  of  the  calibration  curve  for serum  and  HDL  fraction  (5  mmol/L  and  2.5  mmol/L,respectively). The intra- and inter- run variabilities for NCSs were 4.7–10.3% for serum NCS and 3.6–13.6% for HDL-NCS  and  4.6–9.5%  for  serum  NCSs  and  2.5–9.8%  for HDL-NCS,  respectively.  Recovery  studies  showed  satisfactory  results  for  NCSs:  89.8–113.1%  for  serum  NCS  and85.3–95.8% for HDL-NCS. Conclusions:The  method  was  successfully  developed  and optimized. The matrix interference was solved by customising  calibration  curves  for  each  method  and  sample  type.The  measurement  of  NCS  in  HDL  fraction  was  proposed for the first time as potentially useful procedure in biomedical researches.
AB  - Uvod: Neholesterolski steroli (NHS) predstavljaju potencijalne biomarkere homeostaze holesterola. Pored toga, određivanje NHS u HDL frakciji (HDL-NHS) moglo bi da pruži dodatne informacije o efluksu holesterola. Međutim, određivanje NHS metodom tečne hromatografije - masene spektrometrije (LC-MS) je podložno uticaju matriksa usled čega dolazi do sniženja osetljivost metode. Studija je prvenstveno imala za cilj razvoj, optimizaciju i validaciju LC-MS metode za kvantifikaciju NHS u serumu i HDL-NHS. Pored toga, detaljno je ispitan efekat matriksa i metoda primenjena za analizu uzoraka seruma zdravih dobrovoljaca. Metode: Izolacija HDL frakcije je izvršena upotrebom precipitirajućeg reagensa. Efekat matriksa je ispitan poređenjem različitih surogat matriksa regresionom analizom. Validacija je sprovedena u skladu sa FDA-ICH vodičem za validaciju bioanalitičkih metoda. Korišćeni su serumi 20 zdravih dobrovoljaca u cilju kliničke evaluacije metode. Rezultati: Efekat matriksa je iznosio 30% i dalja analiza je pokazala da je holesterol bio glavni uzročnik efekta matriksa. U cilju rešavanja ove interferencije, kalibracione krive za su pripremljene u metanolnom rastvoru holesterola koncentracije 5 mmol/L, a za kvantifikaciju HDL-NHS u metanolnom rastvoru holesterola koncentracije 2,5 mmol/L. Varijacije unutar serije su bile 4,7-10,3% za NHS i 3,6-13,6% za HDL-NHS, a između serija 4,6-9,5% za NHS i 2,5-9,8% za HDL-NHS. Studije prinosa analita su pokazale zadovoljavajuće rezultate: 89,8-113,1% za NHS i 85,3-95,8% za HDL-NHS. Zaključak: Metoda je uspešno optimizovana i validirana. Interferencija usled prisustva holesterola je korigovana upotrebom odgovarajućih kalibracionih krivih za svaku vrstu uzorka. Određivanje HDL-NHS je po prvi put predloženo kao potencijalno korisna procedura u biomedicinskim istraživanjima.
PB  - Belgrade : Society of Medical Biochemists of Serbia
T2  - Journal of Medical Biochemistry
T1  - Determination of non-cholesterol sterols in serum and HDL fraction by LC/MS-ms: Significance of matrix-related interferences
T1  - Određivanje neholesterolskih sterola u serumu i HDL frakciji upotrebom LC/MS-MS - ispitivanje uticaja matriksa
VL  - 39
SP  - 299
EP  - 308
DO  - 10.2478/jomb-2019-0044
ER  - 
@article{
author = "Vladimirov, Sandra and Gojković, Tamara and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna",
year = "2020",
abstract = "Background:Non-cholesterol  sterols  (NCS)  are  promising biomarkers for estimation of cholesterol homeostasis properties.  In  addition,  determination  of  NCS  in  high-density lipoprotein (HDL) fraction (HDL-NCS) could provide information on cholesterol efflux. However, matrix effects interfere in liquid chromatography–mass spectrometry (LC-MS)analysis  of  NCS,  thereby  impairing  the  method  sensitivity.The aims of this study were development, optimization and validation  of  LC-MS  method  for  quantification  of  NCS  in serum  and  HDL-NCS.  Additionally,  matrix  effect  interfer-ences  and  methods  application  in  individual  serum  samples were examined.Methods:HDL precipitating reagent was used for HDL isolation. Matrix effect was examined by comparing different surrogates  by  simple  regression  analysis.  Validation  was conducted according to the FDA-ICH guideline. 20 healthy volunteers were recruited for testing of method application.Results:The  observed  matrix  effect  was  30%,  and  matrix comparison  showed  that  cholesterol  was  the  dominant contributor  to  the  matrix  effect.  Cholesterol  concentration was  adjusted  by  construction  of  the  calibration  curve  for serum  and  HDL  fraction  (5  mmol/L  and  2.5  mmol/L,respectively). The intra- and inter- run variabilities for NCSs were 4.7–10.3% for serum NCS and 3.6–13.6% for HDL-NCS  and  4.6–9.5%  for  serum  NCSs  and  2.5–9.8%  for HDL-NCS,  respectively.  Recovery  studies  showed  satisfactory  results  for  NCSs:  89.8–113.1%  for  serum  NCS  and85.3–95.8% for HDL-NCS. Conclusions:The  method  was  successfully  developed  and optimized. The matrix interference was solved by customising  calibration  curves  for  each  method  and  sample  type.The  measurement  of  NCS  in  HDL  fraction  was  proposed for the first time as potentially useful procedure in biomedical researches., Uvod: Neholesterolski steroli (NHS) predstavljaju potencijalne biomarkere homeostaze holesterola. Pored toga, određivanje NHS u HDL frakciji (HDL-NHS) moglo bi da pruži dodatne informacije o efluksu holesterola. Međutim, određivanje NHS metodom tečne hromatografije - masene spektrometrije (LC-MS) je podložno uticaju matriksa usled čega dolazi do sniženja osetljivost metode. Studija je prvenstveno imala za cilj razvoj, optimizaciju i validaciju LC-MS metode za kvantifikaciju NHS u serumu i HDL-NHS. Pored toga, detaljno je ispitan efekat matriksa i metoda primenjena za analizu uzoraka seruma zdravih dobrovoljaca. Metode: Izolacija HDL frakcije je izvršena upotrebom precipitirajućeg reagensa. Efekat matriksa je ispitan poređenjem različitih surogat matriksa regresionom analizom. Validacija je sprovedena u skladu sa FDA-ICH vodičem za validaciju bioanalitičkih metoda. Korišćeni su serumi 20 zdravih dobrovoljaca u cilju kliničke evaluacije metode. Rezultati: Efekat matriksa je iznosio 30% i dalja analiza je pokazala da je holesterol bio glavni uzročnik efekta matriksa. U cilju rešavanja ove interferencije, kalibracione krive za su pripremljene u metanolnom rastvoru holesterola koncentracije 5 mmol/L, a za kvantifikaciju HDL-NHS u metanolnom rastvoru holesterola koncentracije 2,5 mmol/L. Varijacije unutar serije su bile 4,7-10,3% za NHS i 3,6-13,6% za HDL-NHS, a između serija 4,6-9,5% za NHS i 2,5-9,8% za HDL-NHS. Studije prinosa analita su pokazale zadovoljavajuće rezultate: 89,8-113,1% za NHS i 85,3-95,8% za HDL-NHS. Zaključak: Metoda je uspešno optimizovana i validirana. Interferencija usled prisustva holesterola je korigovana upotrebom odgovarajućih kalibracionih krivih za svaku vrstu uzorka. Određivanje HDL-NHS je po prvi put predloženo kao potencijalno korisna procedura u biomedicinskim istraživanjima.",
publisher = "Belgrade : Society of Medical Biochemists of Serbia",
journal = "Journal of Medical Biochemistry",
title = "Determination of non-cholesterol sterols in serum and HDL fraction by LC/MS-ms: Significance of matrix-related interferences, Određivanje neholesterolskih sterola u serumu i HDL frakciji upotrebom LC/MS-MS - ispitivanje uticaja matriksa",
volume = "39",
pages = "299-308",
doi = "10.2478/jomb-2019-0044"
}
Vladimirov, S., Gojković, T., Zeljković, A., Jelić-Ivanović, Z.,& Spasojević-Kalimanovska, V.. (2020). Determination of non-cholesterol sterols in serum and HDL fraction by LC/MS-ms: Significance of matrix-related interferences. in Journal of Medical Biochemistry
Belgrade : Society of Medical Biochemists of Serbia., 39, 299-308.
https://doi.org/10.2478/jomb-2019-0044
Vladimirov S, Gojković T, Zeljković A, Jelić-Ivanović Z, Spasojević-Kalimanovska V. Determination of non-cholesterol sterols in serum and HDL fraction by LC/MS-ms: Significance of matrix-related interferences. in Journal of Medical Biochemistry. 2020;39:299-308.
doi:10.2478/jomb-2019-0044 .
Vladimirov, Sandra, Gojković, Tamara, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, "Determination of non-cholesterol sterols in serum and HDL fraction by LC/MS-ms: Significance of matrix-related interferences" in Journal of Medical Biochemistry, 39 (2020):299-308,
https://doi.org/10.2478/jomb-2019-0044 . .
8
2
6

Lipid indexes and parameters of lipid peroxidation during physiological pregnancy

Ardalić, Daniela; Stefanović, Aleksandra; Kotur-Stevuljević, Jelena; Ninić, Ana; Spasić, Slavica; Spasojević-Kalimanovska, Vesna; Jelić-Ivanović, Zorana; Miković, Željko

(Walter de Gruyter Gmbh, Berlin, 2019)

TY  - JOUR
AU  - Ardalić, Daniela
AU  - Stefanović, Aleksandra
AU  - Kotur-Stevuljević, Jelena
AU  - Ninić, Ana
AU  - Spasić, Slavica
AU  - Spasojević-Kalimanovska, Vesna
AU  - Jelić-Ivanović, Zorana
AU  - Miković, Željko
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3370
AB  - Background: Specific metabolic changes during physiological pregnancy are characterized by hyperlipidemia and increased oxidative stress. However, these specific changes raise the question of their pro-atherogenic potential during pregnancy and their influence on the risk of developing cardiovascular disease (CVD) in women later in life, as well as complications during pregnancy. The aim of this study was to investigate the changes in lipid indexes and parameters of lipid peroxidation in non-complicated pregnancy in order to estimate their course of change and potential relationship during non-complicated pregnancy. Methods: The study included 43 healthy pregnant women and 38 non-pregnant healthy women, in appropriate ages, as the control group. Lipid parameters and oxidative stress parameters were monitored in a longitudinal study in the first, second and third trimesters, and before delivery during non-complicated pregnancy. Results: Results have shown that lipid indexes rise during pregnancy. The values were significantly increased when compared to the first trimester in all lipid indices and in comparison with the control group. Thyobarbituric acid reactive substances (TBARS) and lipid hydroperoxides (LOOH) were not changed significantly during physiological pregnancy, but LOOH showed a significantly higher value in the first trimester compared with the control group. Prooxidative-antioxidative balance (PAB) significantly increases as pregnancy progresses. Conclusions: We observed the changes in lipids, lipid indexes and parameters that indicate oxidative modification of lipids in physiological pregnancy that may lead to an atherogenic, prooxidant state.
PB  - Walter de Gruyter Gmbh, Berlin
T2  - Journal of Laboratory Medicine
T1  - Lipid indexes and parameters of lipid peroxidation during physiological pregnancy
VL  - 43
IS  - 2
SP  - 93
EP  - 99
DO  - 10.1515/labmed-2018-0026
ER  - 
@article{
author = "Ardalić, Daniela and Stefanović, Aleksandra and Kotur-Stevuljević, Jelena and Ninić, Ana and Spasić, Slavica and Spasojević-Kalimanovska, Vesna and Jelić-Ivanović, Zorana and Miković, Željko",
year = "2019",
abstract = "Background: Specific metabolic changes during physiological pregnancy are characterized by hyperlipidemia and increased oxidative stress. However, these specific changes raise the question of their pro-atherogenic potential during pregnancy and their influence on the risk of developing cardiovascular disease (CVD) in women later in life, as well as complications during pregnancy. The aim of this study was to investigate the changes in lipid indexes and parameters of lipid peroxidation in non-complicated pregnancy in order to estimate their course of change and potential relationship during non-complicated pregnancy. Methods: The study included 43 healthy pregnant women and 38 non-pregnant healthy women, in appropriate ages, as the control group. Lipid parameters and oxidative stress parameters were monitored in a longitudinal study in the first, second and third trimesters, and before delivery during non-complicated pregnancy. Results: Results have shown that lipid indexes rise during pregnancy. The values were significantly increased when compared to the first trimester in all lipid indices and in comparison with the control group. Thyobarbituric acid reactive substances (TBARS) and lipid hydroperoxides (LOOH) were not changed significantly during physiological pregnancy, but LOOH showed a significantly higher value in the first trimester compared with the control group. Prooxidative-antioxidative balance (PAB) significantly increases as pregnancy progresses. Conclusions: We observed the changes in lipids, lipid indexes and parameters that indicate oxidative modification of lipids in physiological pregnancy that may lead to an atherogenic, prooxidant state.",
publisher = "Walter de Gruyter Gmbh, Berlin",
journal = "Journal of Laboratory Medicine",
title = "Lipid indexes and parameters of lipid peroxidation during physiological pregnancy",
volume = "43",
number = "2",
pages = "93-99",
doi = "10.1515/labmed-2018-0026"
}
Ardalić, D., Stefanović, A., Kotur-Stevuljević, J., Ninić, A., Spasić, S., Spasojević-Kalimanovska, V., Jelić-Ivanović, Z.,& Miković, Ž.. (2019). Lipid indexes and parameters of lipid peroxidation during physiological pregnancy. in Journal of Laboratory Medicine
Walter de Gruyter Gmbh, Berlin., 43(2), 93-99.
https://doi.org/10.1515/labmed-2018-0026
Ardalić D, Stefanović A, Kotur-Stevuljević J, Ninić A, Spasić S, Spasojević-Kalimanovska V, Jelić-Ivanović Z, Miković Ž. Lipid indexes and parameters of lipid peroxidation during physiological pregnancy. in Journal of Laboratory Medicine. 2019;43(2):93-99.
doi:10.1515/labmed-2018-0026 .
Ardalić, Daniela, Stefanović, Aleksandra, Kotur-Stevuljević, Jelena, Ninić, Ana, Spasić, Slavica, Spasojević-Kalimanovska, Vesna, Jelić-Ivanović, Zorana, Miković, Željko, "Lipid indexes and parameters of lipid peroxidation during physiological pregnancy" in Journal of Laboratory Medicine, 43, no. 2 (2019):93-99,
https://doi.org/10.1515/labmed-2018-0026 . .
2
2
3

The association between lecithin–cholesterol acyltransferase activity and fatty liver index

Janać, Jelena; Zeljković, Aleksandra; Jelić-Ivanović, Zorana; Dimitrijević-Srećković, Vesna; Miljković, Milica; Stefanović, Aleksandra; Munjas, Jelena; Vekić, Jelena; Kotur-Stevuljević, Jelena; Spasojević-Kalimanovska, Vesna

(Sage Publications Ltd, 2019)

TY  - JOUR
AU  - Janać, Jelena
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Dimitrijević-Srećković, Vesna
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Munjas, Jelena
AU  - Vekić, Jelena
AU  - Kotur-Stevuljević, Jelena
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3293
AB  - Background: Non-alcoholic fatty liver disease is a frequent ailment with known complications, including those within the cardiovascular system. Associations between several indicators of high-density lipoprotein metabolism and function with clinical and laboratory parameters for the assessment of fatty liver index, a surrogate marker of non-alcoholic fatty liver disease, were evaluated. Methods: The study comprised 130 patients classified according to fatty liver index values: fatty liver index  lt  30, fatty liver index 30–59 (the intermediate group) and fatty liver index ⩾ 60. Lecithin–cholesterol acyltransferase and cholesteryl ester transfer protein activities were determined. Paraoxonase 1 concentration and its activity, paraoxonase 3 concentration and high-density lipoprotein subclass distribution were assessed. Results: Increased lecithin–cholesterol acyltransferase activity correlated with increased fatty liver index (P  lt  0.001). Paraoxonase 3 concentration was lower in the fatty liver index ⩾ 60 group compared with the fatty liver index  lt  30 group (P  lt  0.05). Cholesteryl ester transfer protein activity, paraoxonase 1 concentration and its activity did not significantly differ across the fatty liver index groups. The relative proportion of small-sized high-density lipoprotein 3 subclass was higher in the fatty liver index ⩾ 60 group compared with the other two fatty liver index groups (P  lt  0.01). Lecithin–cholesterol acyltransferase activity positively associated with the fatty liver index ⩾ 60 group and remained significant after adjustment for other potential confounders. Only the triglyceride concentration remained significantly associated with lecithin–cholesterol acyltransferase activity when the parameters that constitute the fatty liver index equation were examined. Conclusions: Higher lecithin–cholesterol acyltransferase activity is associated with elevated fatty liver index values. Significant independent association between triglycerides and lecithin–cholesterol acyltransferase activity might indicate a role of hypertriglyceridaemia in alterations of lecithin–cholesterol acyltransferase activity in individuals with elevated fatty liver index.
PB  - Sage Publications Ltd
T2  - Annals of Clinical Biochemistry
T1  - The association between lecithin–cholesterol acyltransferase activity and fatty liver index
VL  - 56
IS  - 5
SP  - 583
EP  - 592
DO  - 10.1177/0004563219853596
ER  - 
@article{
author = "Janać, Jelena and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Dimitrijević-Srećković, Vesna and Miljković, Milica and Stefanović, Aleksandra and Munjas, Jelena and Vekić, Jelena and Kotur-Stevuljević, Jelena and Spasojević-Kalimanovska, Vesna",
year = "2019",
abstract = "Background: Non-alcoholic fatty liver disease is a frequent ailment with known complications, including those within the cardiovascular system. Associations between several indicators of high-density lipoprotein metabolism and function with clinical and laboratory parameters for the assessment of fatty liver index, a surrogate marker of non-alcoholic fatty liver disease, were evaluated. Methods: The study comprised 130 patients classified according to fatty liver index values: fatty liver index  lt  30, fatty liver index 30–59 (the intermediate group) and fatty liver index ⩾ 60. Lecithin–cholesterol acyltransferase and cholesteryl ester transfer protein activities were determined. Paraoxonase 1 concentration and its activity, paraoxonase 3 concentration and high-density lipoprotein subclass distribution were assessed. Results: Increased lecithin–cholesterol acyltransferase activity correlated with increased fatty liver index (P  lt  0.001). Paraoxonase 3 concentration was lower in the fatty liver index ⩾ 60 group compared with the fatty liver index  lt  30 group (P  lt  0.05). Cholesteryl ester transfer protein activity, paraoxonase 1 concentration and its activity did not significantly differ across the fatty liver index groups. The relative proportion of small-sized high-density lipoprotein 3 subclass was higher in the fatty liver index ⩾ 60 group compared with the other two fatty liver index groups (P  lt  0.01). Lecithin–cholesterol acyltransferase activity positively associated with the fatty liver index ⩾ 60 group and remained significant after adjustment for other potential confounders. Only the triglyceride concentration remained significantly associated with lecithin–cholesterol acyltransferase activity when the parameters that constitute the fatty liver index equation were examined. Conclusions: Higher lecithin–cholesterol acyltransferase activity is associated with elevated fatty liver index values. Significant independent association between triglycerides and lecithin–cholesterol acyltransferase activity might indicate a role of hypertriglyceridaemia in alterations of lecithin–cholesterol acyltransferase activity in individuals with elevated fatty liver index.",
publisher = "Sage Publications Ltd",
journal = "Annals of Clinical Biochemistry",
title = "The association between lecithin–cholesterol acyltransferase activity and fatty liver index",
volume = "56",
number = "5",
pages = "583-592",
doi = "10.1177/0004563219853596"
}
Janać, J., Zeljković, A., Jelić-Ivanović, Z., Dimitrijević-Srećković, V., Miljković, M., Stefanović, A., Munjas, J., Vekić, J., Kotur-Stevuljević, J.,& Spasojević-Kalimanovska, V.. (2019). The association between lecithin–cholesterol acyltransferase activity and fatty liver index. in Annals of Clinical Biochemistry
Sage Publications Ltd., 56(5), 583-592.
https://doi.org/10.1177/0004563219853596
Janać J, Zeljković A, Jelić-Ivanović Z, Dimitrijević-Srećković V, Miljković M, Stefanović A, Munjas J, Vekić J, Kotur-Stevuljević J, Spasojević-Kalimanovska V. The association between lecithin–cholesterol acyltransferase activity and fatty liver index. in Annals of Clinical Biochemistry. 2019;56(5):583-592.
doi:10.1177/0004563219853596 .
Janać, Jelena, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Dimitrijević-Srećković, Vesna, Miljković, Milica, Stefanović, Aleksandra, Munjas, Jelena, Vekić, Jelena, Kotur-Stevuljević, Jelena, Spasojević-Kalimanovska, Vesna, "The association between lecithin–cholesterol acyltransferase activity and fatty liver index" in Annals of Clinical Biochemistry, 56, no. 5 (2019):583-592,
https://doi.org/10.1177/0004563219853596 . .
8
2
7

Significance of glycosylated haemoglobin determination for the assessment of lowerextremity amputation risk in patients with diabetic foot

Stefanović, Tatjana; Bosić, Srećko; Vekić, Jelena; Spasojević-Kalimanovska, Vesna; Todorović, Vesna; Pijanović, Marina; Zeljković, Aleksandra; Stefanović, Aleksandra; Jelić-Ivanović, Zorana

(Pharmaceutical Association of Serbia, 2019)

TY  - JOUR
AU  - Stefanović, Tatjana
AU  - Bosić, Srećko
AU  - Vekić, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Todorović, Vesna
AU  - Pijanović, Marina
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Jelić-Ivanović, Zorana
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3667
AB  - Glikohemoglobin  (HbA1c)  je  važan  parametar  za  praćenje  dugoročne  metaboličke kontrole  i  procenu  rizika  za  razvoj  hroničnih  komplikacija  kod pacijenata  sa  dijabetes melitusom (DM). U ovoj studiji ispitivali smo povezanost postignute metaboličke kontrole u tipu  2  DM  sa  rizikom  za  razvoj  i  primenjenim  modalitetom  lečenja  sindroma  dijabetesnog stopala (SDS). U istraživanju je učestvovalo 111 pacijenata (80 muškaraca i 31 žena) sa tipom 2 DM, starosti 65,5 ± 9,8 godina. Kod 41 pacijenta SDS je lečen neoperativnim (konzervativnim) pristupom, hirurška intervencija manjeg obima (amputacija u predelu stopala) je izvršena kod 41,  a  opsežna  hirurška  intervencija  (amputacija  u  predelu  potkolenice)  kod  29  pacijenata. Koncentracije  biohemijskih  parametara  i  HbA1c  su  određene  standardnim  laboratorijskim metodama. U ispitivanoj grupi najučestaliji faktor rizika za nastanak SDS (82% pacijenata) bila je  neadekvatna  glikoregulacija  (HbA1c>8%).  Utvrdili  smo  da  su  pacijenti  koji  su  lečeni hirurškim putem imali statistički značajno više vrednosti HbA1c u poređenju sa pacijentima koji su  lečeni  neoperativnim  pristupom  (P<0,05).  Ukupan  broj  pacijenata  koji  je  podvrgnut hirurškom  lečenju  bio  je  značajno  veći  u  grupi  sa  neadekvatnom glikoregulacijom  (68,2% pacijenata  sa  neadekvatnom vs.  40%  pacijenata  sa  adekvatnom  glikoregulacijom; P<0,05). Utvrdili smo da je verovatnoća za amputaciju 3,2 puta veća ukoliko pacijent ima neadekvatnu glikoregulaciju  (OR=3,21;  95%CI:1,18-8,69; P<0,05).  Naši  rezultati  su  pokazali  da  se održavanjem dobre metaboličke kontrole u tipu 2 DM smanjuje rizik za razvoj SDS, ali i stepen invazivnosti postupka lečenja SDS.
AB  - Glycosylated hemoglobin (HbA1c) is important parameter for the assessment of long term metabolic control and risk for development of chronic complications in patients with diabetes mellitus (DM). This study investigates associations between achieved metabolic control in type 2 DM with the risk for the development of diabetic foot (DF) and its treatment modalities. The study included 111 patients (80 men and 31 women) with type 2 DM, aged 65.5±9.8 years. In 41 patients DF was treated by a conservative approach, 41 patients underwent a minor limb amputation (foot amputation) and 29 patients underwent a major limb amputation (below-knee amputation).  The  levels  of  HbA1c  and  serum  biochemical  parameters  were  measured  by standard laboratory methods. The most frequent risk factor for DF in the examined group (82% patients) was poor glycaemic control (HbA1c>8%). The level of HbA1c was significantly higher in surgically treated patients than in the conservatively treated group (P<0.05). The number of patients  who  underwent  surgical  treatment  were  significantly  higher  in  the  group  with  poor glycaemic control (62.8% patients with poor glycaemic control vs. 40% patients with optimal glycaemic control; P<0.05). We found that the patients with poor glycaemic control had 3.2 times  higher  risk  for  amputation  (OR=3.21;  95%CI:1.18-8.69; P<0.05).  In  conclusion,  our results  demonstrated  that  optimal  metabolic  control  in  type  2  DM  reduces  the  risk  for  DF development, as well as the invasiveness of DF treatment.
PB  - Pharmaceutical Association of Serbia
T2  - Arhiv za farmaciju
T1  - Significance of glycosylated haemoglobin determination for the assessment of lowerextremity amputation risk in patients with diabetic foot
T1  - Značaj određivanja glikohemoglobina u proceni rizika od amputacija kod pacijenata sa sindromom dijabetesnog stopala
VL  - 69
IS  - 2
SP  - 51
EP  - 66
DO  - 10.5937/arhfarm1902051X
ER  - 
@article{
author = "Stefanović, Tatjana and Bosić, Srećko and Vekić, Jelena and Spasojević-Kalimanovska, Vesna and Todorović, Vesna and Pijanović, Marina and Zeljković, Aleksandra and Stefanović, Aleksandra and Jelić-Ivanović, Zorana",
year = "2019",
abstract = "Glikohemoglobin  (HbA1c)  je  važan  parametar  za  praćenje  dugoročne  metaboličke kontrole  i  procenu  rizika  za  razvoj  hroničnih  komplikacija  kod pacijenata  sa  dijabetes melitusom (DM). U ovoj studiji ispitivali smo povezanost postignute metaboličke kontrole u tipu  2  DM  sa  rizikom  za  razvoj  i  primenjenim  modalitetom  lečenja  sindroma  dijabetesnog stopala (SDS). U istraživanju je učestvovalo 111 pacijenata (80 muškaraca i 31 žena) sa tipom 2 DM, starosti 65,5 ± 9,8 godina. Kod 41 pacijenta SDS je lečen neoperativnim (konzervativnim) pristupom, hirurška intervencija manjeg obima (amputacija u predelu stopala) je izvršena kod 41,  a  opsežna  hirurška  intervencija  (amputacija  u  predelu  potkolenice)  kod  29  pacijenata. Koncentracije  biohemijskih  parametara  i  HbA1c  su  određene  standardnim  laboratorijskim metodama. U ispitivanoj grupi najučestaliji faktor rizika za nastanak SDS (82% pacijenata) bila je  neadekvatna  glikoregulacija  (HbA1c>8%).  Utvrdili  smo  da  su  pacijenti  koji  su  lečeni hirurškim putem imali statistički značajno više vrednosti HbA1c u poređenju sa pacijentima koji su  lečeni  neoperativnim  pristupom  (P<0,05).  Ukupan  broj  pacijenata  koji  je  podvrgnut hirurškom  lečenju  bio  je  značajno  veći  u  grupi  sa  neadekvatnom glikoregulacijom  (68,2% pacijenata  sa  neadekvatnom vs.  40%  pacijenata  sa  adekvatnom  glikoregulacijom; P<0,05). Utvrdili smo da je verovatnoća za amputaciju 3,2 puta veća ukoliko pacijent ima neadekvatnu glikoregulaciju  (OR=3,21;  95%CI:1,18-8,69; P<0,05).  Naši  rezultati  su  pokazali  da  se održavanjem dobre metaboličke kontrole u tipu 2 DM smanjuje rizik za razvoj SDS, ali i stepen invazivnosti postupka lečenja SDS., Glycosylated hemoglobin (HbA1c) is important parameter for the assessment of long term metabolic control and risk for development of chronic complications in patients with diabetes mellitus (DM). This study investigates associations between achieved metabolic control in type 2 DM with the risk for the development of diabetic foot (DF) and its treatment modalities. The study included 111 patients (80 men and 31 women) with type 2 DM, aged 65.5±9.8 years. In 41 patients DF was treated by a conservative approach, 41 patients underwent a minor limb amputation (foot amputation) and 29 patients underwent a major limb amputation (below-knee amputation).  The  levels  of  HbA1c  and  serum  biochemical  parameters  were  measured  by standard laboratory methods. The most frequent risk factor for DF in the examined group (82% patients) was poor glycaemic control (HbA1c>8%). The level of HbA1c was significantly higher in surgically treated patients than in the conservatively treated group (P<0.05). The number of patients  who  underwent  surgical  treatment  were  significantly  higher  in  the  group  with  poor glycaemic control (62.8% patients with poor glycaemic control vs. 40% patients with optimal glycaemic control; P<0.05). We found that the patients with poor glycaemic control had 3.2 times  higher  risk  for  amputation  (OR=3.21;  95%CI:1.18-8.69; P<0.05).  In  conclusion,  our results  demonstrated  that  optimal  metabolic  control  in  type  2  DM  reduces  the  risk  for  DF development, as well as the invasiveness of DF treatment.",
publisher = "Pharmaceutical Association of Serbia",
journal = "Arhiv za farmaciju",
title = "Significance of glycosylated haemoglobin determination for the assessment of lowerextremity amputation risk in patients with diabetic foot, Značaj određivanja glikohemoglobina u proceni rizika od amputacija kod pacijenata sa sindromom dijabetesnog stopala",
volume = "69",
number = "2",
pages = "51-66",
doi = "10.5937/arhfarm1902051X"
}
Stefanović, T., Bosić, S., Vekić, J., Spasojević-Kalimanovska, V., Todorović, V., Pijanović, M., Zeljković, A., Stefanović, A.,& Jelić-Ivanović, Z.. (2019). Significance of glycosylated haemoglobin determination for the assessment of lowerextremity amputation risk in patients with diabetic foot. in Arhiv za farmaciju
Pharmaceutical Association of Serbia., 69(2), 51-66.
https://doi.org/10.5937/arhfarm1902051X
Stefanović T, Bosić S, Vekić J, Spasojević-Kalimanovska V, Todorović V, Pijanović M, Zeljković A, Stefanović A, Jelić-Ivanović Z. Significance of glycosylated haemoglobin determination for the assessment of lowerextremity amputation risk in patients with diabetic foot. in Arhiv za farmaciju. 2019;69(2):51-66.
doi:10.5937/arhfarm1902051X .
Stefanović, Tatjana, Bosić, Srećko, Vekić, Jelena, Spasojević-Kalimanovska, Vesna, Todorović, Vesna, Pijanović, Marina, Zeljković, Aleksandra, Stefanović, Aleksandra, Jelić-Ivanović, Zorana, "Significance of glycosylated haemoglobin determination for the assessment of lowerextremity amputation risk in patients with diabetic foot" in Arhiv za farmaciju, 69, no. 2 (2019):51-66,
https://doi.org/10.5937/arhfarm1902051X . .

Obstructive sleep apnea and cardiometabolic risk

Vekić, Jelena; Jelić-Ivanović, Zorana; Zeljković, Aleksandra; Stefanović, Aleksandra; Spasojević-Kalimanovska, Vesna

(Beograd: Savez farmaceutskih udruženja Srbije, 2019)

TY  - JOUR
AU  - Vekić, Jelena
AU  - Jelić-Ivanović, Zorana
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3564
AB  - Obstructive sleep apnea (OSA) is a chronic, progressive disorder with a high prevalence in the population. Without timely diagnosis and therapy OSA can significantly affect the quality of life of the patients. OSA is a common co-morbidity in patients with metabolic syndrome (MS) and cardiovascular disease (CVD) and is an important risk factor for their development. The presence of untreated, severe OSA is associated with an increase in total and cardiovascular mortality. Numerous studies have pointed to the relationship between MS and OSA, and this phenomenon  was  described  as  syndrome  Z.  Investigation  of  the  causal relationship between OSA  and  CVD  has  been  greatly  confounded  by  the  complex  nature  of  the  disease  itself. Cardiometabolic  risk  in  OSA  is  associated  with  arterial  hypertension,  insulin  resistance, endothelial  dysfunction,  inflammation,  dyslipidemia,  and  oxidative  stress.  The  treatment  of OSA is now most effectively performed by continuous positive airway pressure (CPAP), a type of  non-invasive  ventilation  which  prevents  the  onset  of  sleep  apnea.  The  results  of  clinical studies  have  shown  that  CPAP  therapy  significantly  improves  haemodynamic  parameters, regulates  hypertension,  increases  insulin  sensitivity,  and  corrects  dyslipidemia.  Future investigations  should  clarify  whether  sleep  apnea  is  a  risk  factor  for  CVD per  se or is a consequence of a broader pathophysiological process, of which OSA is part.
AB  - Opstruktivna  apneja  u  snu  (OSA)  je  hronično  progresivno  oboljenje  sa  visokom prevalencom  u  populaciji  koje,  bez  pravovremene  dijagnoze  i  terapije,  može  dovesti  do značajnih posledica po kvalitet života pacijenata. OSA je čest komorbiditet  kod pacijenata sa metaboličkim sindromom (MS) i kardiovaskularnim bolestima (KVB) i predstavlja važan faktor rizika za nastanak ovih oboljenja, a prisustvo nelečenog, teškog oblika OSA povezano je sa porastom ukupnog i mortaliteta usled koronarnih događaja. Brojne studije su ukazale na vezu između MS i OSA, te je ovaj fenomen opisan kao poseban poremećaj - sindrom Z. Istraživanje uzročno-posledične veze između OSA i KVB je u velikoj meri otežano kompleksnom prirodom samog  oboljenja.  Smatra  se  da  je  kardiometabolički  rizik  u  OSA udružen  sa  arterijskom hipertenzijom,   insulinskom   rezistencijom,   endotelnom   disfunkcijom,   inflamacijom, dislipidemijom  i  oksidativnim  stresom.  Lečenje  OSA  se  danas  najefikasnije  sprovodi neinvazivnom  ventilacijom,  pomoću  uređaja  koji  obezbeđuje  pozitivan  pritisak  u  gornjim disajnim putevima (eng. continuous  positive  airway  pressure, CPAP) i na taj način sprečava pojavu  apneja  tokom  spavanja.  Rezultati  kliničkih  studija  su  pokazali  da  CPAP  terapija značajno  poboljšava  hemodinamske  parametre,  reguliše  hipertenziju,  povećava  osetljivost  na insulin i koriguje dislipidemiju. Buduća istraživanja bi trebalo da rasvetle da li je apneja u snu faktor rizika za KVB per  se ili je ta veza posledica šireg patofiziološkog procesa, čiji je deo i OSA.
PB  - Beograd: Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Obstructive sleep apnea and cardiometabolic risk
T1  - Opstruktivna apneja u snu i kardiometabolički rizik
VL  - 69
IS  - 3
SP  - 153
EP  - 164
DO  - 10.5937/arhfarm1903153
ER  - 
@article{
author = "Vekić, Jelena and Jelić-Ivanović, Zorana and Zeljković, Aleksandra and Stefanović, Aleksandra and Spasojević-Kalimanovska, Vesna",
year = "2019",
abstract = "Obstructive sleep apnea (OSA) is a chronic, progressive disorder with a high prevalence in the population. Without timely diagnosis and therapy OSA can significantly affect the quality of life of the patients. OSA is a common co-morbidity in patients with metabolic syndrome (MS) and cardiovascular disease (CVD) and is an important risk factor for their development. The presence of untreated, severe OSA is associated with an increase in total and cardiovascular mortality. Numerous studies have pointed to the relationship between MS and OSA, and this phenomenon  was  described  as  syndrome  Z.  Investigation  of  the  causal relationship between OSA  and  CVD  has  been  greatly  confounded  by  the  complex  nature  of  the  disease  itself. Cardiometabolic  risk  in  OSA  is  associated  with  arterial  hypertension,  insulin  resistance, endothelial  dysfunction,  inflammation,  dyslipidemia,  and  oxidative  stress.  The  treatment  of OSA is now most effectively performed by continuous positive airway pressure (CPAP), a type of  non-invasive  ventilation  which  prevents  the  onset  of  sleep  apnea.  The  results  of  clinical studies  have  shown  that  CPAP  therapy  significantly  improves  haemodynamic  parameters, regulates  hypertension,  increases  insulin  sensitivity,  and  corrects  dyslipidemia.  Future investigations  should  clarify  whether  sleep  apnea  is  a  risk  factor  for  CVD per  se or is a consequence of a broader pathophysiological process, of which OSA is part., Opstruktivna  apneja  u  snu  (OSA)  je  hronično  progresivno  oboljenje  sa  visokom prevalencom  u  populaciji  koje,  bez  pravovremene  dijagnoze  i  terapije,  može  dovesti  do značajnih posledica po kvalitet života pacijenata. OSA je čest komorbiditet  kod pacijenata sa metaboličkim sindromom (MS) i kardiovaskularnim bolestima (KVB) i predstavlja važan faktor rizika za nastanak ovih oboljenja, a prisustvo nelečenog, teškog oblika OSA povezano je sa porastom ukupnog i mortaliteta usled koronarnih događaja. Brojne studije su ukazale na vezu između MS i OSA, te je ovaj fenomen opisan kao poseban poremećaj - sindrom Z. Istraživanje uzročno-posledične veze između OSA i KVB je u velikoj meri otežano kompleksnom prirodom samog  oboljenja.  Smatra  se  da  je  kardiometabolički  rizik  u  OSA udružen  sa  arterijskom hipertenzijom,   insulinskom   rezistencijom,   endotelnom   disfunkcijom,   inflamacijom, dislipidemijom  i  oksidativnim  stresom.  Lečenje  OSA  se  danas  najefikasnije  sprovodi neinvazivnom  ventilacijom,  pomoću  uređaja  koji  obezbeđuje  pozitivan  pritisak  u  gornjim disajnim putevima (eng. continuous  positive  airway  pressure, CPAP) i na taj način sprečava pojavu  apneja  tokom  spavanja.  Rezultati  kliničkih  studija  su  pokazali  da  CPAP  terapija značajno  poboljšava  hemodinamske  parametre,  reguliše  hipertenziju,  povećava  osetljivost  na insulin i koriguje dislipidemiju. Buduća istraživanja bi trebalo da rasvetle da li je apneja u snu faktor rizika za KVB per  se ili je ta veza posledica šireg patofiziološkog procesa, čiji je deo i OSA.",
publisher = "Beograd: Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Obstructive sleep apnea and cardiometabolic risk, Opstruktivna apneja u snu i kardiometabolički rizik",
volume = "69",
number = "3",
pages = "153-164",
doi = "10.5937/arhfarm1903153"
}
Vekić, J., Jelić-Ivanović, Z., Zeljković, A., Stefanović, A.,& Spasojević-Kalimanovska, V.. (2019). Obstructive sleep apnea and cardiometabolic risk. in Arhiv za farmaciju
Beograd: Savez farmaceutskih udruženja Srbije., 69(3), 153-164.
https://doi.org/10.5937/arhfarm1903153
Vekić J, Jelić-Ivanović Z, Zeljković A, Stefanović A, Spasojević-Kalimanovska V. Obstructive sleep apnea and cardiometabolic risk. in Arhiv za farmaciju. 2019;69(3):153-164.
doi:10.5937/arhfarm1903153 .
Vekić, Jelena, Jelić-Ivanović, Zorana, Zeljković, Aleksandra, Stefanović, Aleksandra, Spasojević-Kalimanovska, Vesna, "Obstructive sleep apnea and cardiometabolic risk" in Arhiv za farmaciju, 69, no. 3 (2019):153-164,
https://doi.org/10.5937/arhfarm1903153 . .

Dyslipidemia in type 2 diabetes mellitus

Stefanović, Aleksandra; Zeljković, Aleksandra; Vekić, Jelena; Spasojević-Kalimanovska, Vesna; Jelić-Ivanović, Zorana; Spasić, Slavica

(Beograd : Savez farmaceutskih udruženja Srbije, 2019)

TY  - JOUR
AU  - Stefanović, Aleksandra
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Jelić-Ivanović, Zorana
AU  - Spasić, Slavica
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3560
AB  - Type  2  diabetes  mellitus  is  a  chronic  high-prevalence  metabolic  disease,  which  is characterized by hyperglycaemia, but also with lipid and protein metabolism disorders. Patients with  type  2  diabetes  have  a  high  risk  for  cardiovascular  disease  (CVD)  development  and dyslipidemia is considered as a key marker of this increased risk. Hypertriglyceridemia, reduced high  density  lipoprotein  cholesterol  (HDL-c)  concentrations,  and  a  shift  in  low-density lipoprotein  particles  (LDL)  distribution  toward  the  small,  triglycerides-rich  particles,  are  the most important changes in the lipid profile in diabetes.Type 2 diabetes is a metabolic disorder associated with low grade inflammation and oxidative stress, so in this condition high density lipoprotein  particles  (HDL)  also  undergo  structural  and  functional  changes  and,  as  a consequence, lose their atheroprotective role. Dyslipidemia treatment in type 2 diabetes patients younger than 40 and without any other risk factor for CVD development starts with changes in a lifestyle, but in patients older than 40 years, first line medications are statins.Glycemic and lipid control in type 2 diabetes patients significantly reduces CVD risk.
AB  - Dijabetes melitus tip 2 je hronično oboljenje sa visokom prevalencom, koje se karakteriše hiperglikemijom,  ali  i  poremećajima  u  metabolizmu  lipida  i  proteina.  Pacijenti  sa  tipom  2 dijabetesa imaju visok rizik za razvoj kardiovaskularnih bolesti (KVB) i upravo se dislipidemija smatra  ključnim  uzročnikom  ovog  povećanog  rizika.  Hipertrigliceridemija,  snižena koncentracija  holesterola  u  lipoproteinskim  česticama  visoke  gustine  (HDL-h)  i  promena  u raspodeli  lipoproteinskih  čestica  niske  gustine  (LDL)  u  smeru  većeg  udela  malih  čestica, bogatih  trigliceridima,  predstavljaju  najvažnije  promene  lipidnog  profila  koje  se  odnose  na dislipidemiju  u  dijabetesu.  Kako je  dijabetes  stanje  kontinuirane  blage  inflamacije  niskog stepena  i  stalne  produkcije  slobodnih  radikala,  HDL  lipoproteinske  čestice  takođe  podležu strukturnim  i  funkcionalnim  promenama,  usled  čega  gube  svoje  ateroprotektivne  osobine. Terapija dislipidemije kod pacijenata mlađih od 40 godina bez prisutnih drugih faktora rizika za razvoj KVB počinje promenom životnog stila, a kod pacijenata starijih od 40 godina lekovi izbora u terapiji su statini. Glikemijska i lipidna kontrola kod pacijenata sa tipom 2 dijabetesa značajno umanjuje rizik od nastanka KVB.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Dyslipidemia in type 2 diabetes mellitus
T1  - Dislipidemija u dijabetes melitusu tip 2
VL  - 69
IS  - 5
SP  - 338
EP  - 348
DO  - 10.5937/arhfarm1905338S
ER  - 
@article{
author = "Stefanović, Aleksandra and Zeljković, Aleksandra and Vekić, Jelena and Spasojević-Kalimanovska, Vesna and Jelić-Ivanović, Zorana and Spasić, Slavica",
year = "2019",
abstract = "Type  2  diabetes  mellitus  is  a  chronic  high-prevalence  metabolic  disease,  which  is characterized by hyperglycaemia, but also with lipid and protein metabolism disorders. Patients with  type  2  diabetes  have  a  high  risk  for  cardiovascular  disease  (CVD)  development  and dyslipidemia is considered as a key marker of this increased risk. Hypertriglyceridemia, reduced high  density  lipoprotein  cholesterol  (HDL-c)  concentrations,  and  a  shift  in  low-density lipoprotein  particles  (LDL)  distribution  toward  the  small,  triglycerides-rich  particles,  are  the most important changes in the lipid profile in diabetes.Type 2 diabetes is a metabolic disorder associated with low grade inflammation and oxidative stress, so in this condition high density lipoprotein  particles  (HDL)  also  undergo  structural  and  functional  changes  and,  as  a consequence, lose their atheroprotective role. Dyslipidemia treatment in type 2 diabetes patients younger than 40 and without any other risk factor for CVD development starts with changes in a lifestyle, but in patients older than 40 years, first line medications are statins.Glycemic and lipid control in type 2 diabetes patients significantly reduces CVD risk., Dijabetes melitus tip 2 je hronično oboljenje sa visokom prevalencom, koje se karakteriše hiperglikemijom,  ali  i  poremećajima  u  metabolizmu  lipida  i  proteina.  Pacijenti  sa  tipom  2 dijabetesa imaju visok rizik za razvoj kardiovaskularnih bolesti (KVB) i upravo se dislipidemija smatra  ključnim  uzročnikom  ovog  povećanog  rizika.  Hipertrigliceridemija,  snižena koncentracija  holesterola  u  lipoproteinskim  česticama  visoke  gustine  (HDL-h)  i  promena  u raspodeli  lipoproteinskih  čestica  niske  gustine  (LDL)  u  smeru  većeg  udela  malih  čestica, bogatih  trigliceridima,  predstavljaju  najvažnije  promene  lipidnog  profila  koje  se  odnose  na dislipidemiju  u  dijabetesu.  Kako je  dijabetes  stanje  kontinuirane  blage  inflamacije  niskog stepena  i  stalne  produkcije  slobodnih  radikala,  HDL  lipoproteinske  čestice  takođe  podležu strukturnim  i  funkcionalnim  promenama,  usled  čega  gube  svoje  ateroprotektivne  osobine. Terapija dislipidemije kod pacijenata mlađih od 40 godina bez prisutnih drugih faktora rizika za razvoj KVB počinje promenom životnog stila, a kod pacijenata starijih od 40 godina lekovi izbora u terapiji su statini. Glikemijska i lipidna kontrola kod pacijenata sa tipom 2 dijabetesa značajno umanjuje rizik od nastanka KVB.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Dyslipidemia in type 2 diabetes mellitus, Dislipidemija u dijabetes melitusu tip 2",
volume = "69",
number = "5",
pages = "338-348",
doi = "10.5937/arhfarm1905338S"
}
Stefanović, A., Zeljković, A., Vekić, J., Spasojević-Kalimanovska, V., Jelić-Ivanović, Z.,& Spasić, S.. (2019). Dyslipidemia in type 2 diabetes mellitus. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 69(5), 338-348.
https://doi.org/10.5937/arhfarm1905338S
Stefanović A, Zeljković A, Vekić J, Spasojević-Kalimanovska V, Jelić-Ivanović Z, Spasić S. Dyslipidemia in type 2 diabetes mellitus. in Arhiv za farmaciju. 2019;69(5):338-348.
doi:10.5937/arhfarm1905338S .
Stefanović, Aleksandra, Zeljković, Aleksandra, Vekić, Jelena, Spasojević-Kalimanovska, Vesna, Jelić-Ivanović, Zorana, Spasić, Slavica, "Dyslipidemia in type 2 diabetes mellitus" in Arhiv za farmaciju, 69, no. 5 (2019):338-348,
https://doi.org/10.5937/arhfarm1905338S . .
5
3

Opstruktivna apneja u snu i kardiometabolički rizik

Vekić, Jelena; Jelić-Ivanović, Zorana; Zeljković, Aleksandra; Stefanović, Aleksandra; Spasojević-Kalimanovska, Vesna

(Beograd : Savez farmaceutskih udruženja Srbije, 2019)

TY  - JOUR
AU  - Vekić, Jelena
AU  - Jelić-Ivanović, Zorana
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3491
AB  - Opstruktivna  apneja  u  snu  (OSA)  je  hronično  progresivno  oboljenje  sa  visokom prevalencom  u  populaciji  koje,  bez  pravovremene  dijagnoze  i  terapije,  može  dovesti  do značajnih posledica po kvalitet života pacijenata. OSA je čest komorbiditet  kod pacijenata sa metaboličkim sindromom (MS) i kardiovaskularnim bolestima (KVB) i predstavlja važan faktor rizika za nastanak ovih oboljenja, a prisustvo nelečenog, teškog oblika OSA povezano je sa porastom ukupnog i mortaliteta usled koronarnih događaja. Brojne studije su ukazale na vezu između MS i OSA, te je ovaj fenomen opisan kao poseban poremećaj - sindrom Z. Istraživanje uzročno-posledične veze između OSA i KVB je u velikoj meri otežano kompleksnom prirodom samog  oboljenja.  Smatra  se  da  je  kardiometabolički  rizik  u  OSA udružen  sa  arterijskom hipertenzijom,   insulinskom   rezistencijom,   endotelnom   disfunkcijom,   inflamacijom, dislipidemijom  i  oksidativnim  stresom.  Lečenje  OSA  se  danas  najefikasnije  sprovodi neinvazivnom  ventilacijom,  pomoću  uređaja  koji  obezbeđuje  pozitivan  pritisak  u  gornjim disajnim putevima (eng. continuous  positive  airway  pressure, CPAP) i na taj način sprečava pojavu  apneja  tokom  spavanja.  Rezultati  kliničkih  studija  su  pokazali  da  CPAP  terapija značajno  poboljšava  hemodinamske  parametre,  reguliše  hipertenziju,  povećava  osetljivost  na insulin i koriguje dislipidemiju. Buduća istraživanja bi trebalo da rasvetle da li je apneja u snu faktor rizika za KVB per  se ili je ta veza posledica šireg patofiziološkog procesa, čiji je deo i OSA.
AB  - Obstructive sleep apnea (OSA) is a chronic, progressive disorder with a high prevalence in the population. Without timely diagnosis and therapy OSA can significantly affect the quality of life of the patients. OSA is a common co-morbidity in patients with metabolic syndrome (MS) and cardiovascular disease (CVD) and is an important risk factor for their development. The presence of untreated, severe OSA is associated with an increase in total and cardiovascular mortality. Numerous studies have pointed to the relationship between MS and OSA, and this phenomenon  was  described  as  syndrome  Z.  Investigation  of  the  causal relationship between OSA  and  CVD  has  been  greatly  confounded  by  the  complex  nature  of  the  disease  itself. Cardiometabolic  risk  in  OSA  is  associated  with  arterial  hypertension,  insulin  resistance, endothelial  dysfunction,  inflammation,  dyslipidemia,  and  oxidative  stress.  The  treatment  of OSA is now most effectively performed by continuous positive airway pressure (CPAP), a type of  non-invasive  ventilation  which  prevents  the  onset  of  sleep  apnea.  The  results  of  clinical studies  have  shown  that  CPAP  therapy  significantly  improves  haemodynamic  parameters, regulates  hypertension,  increases  insulin  sensitivity,  and  corrects  dyslipidemia.  Future investigations  should  clarify  whether  sleep  apnea  is  a  risk  factor  for  CVD per  se or is a consequence of a broader pathophysiological process, of which OSA is part.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Opstruktivna apneja u snu i kardiometabolički rizik
T1  - Obstructive sleep apnea and cardiometabolic risk
VL  - 69
IS  - 3
SP  - 153
EP  - 164
DO  - 10.5937/arhfarm1903153
ER  - 
@article{
author = "Vekić, Jelena and Jelić-Ivanović, Zorana and Zeljković, Aleksandra and Stefanović, Aleksandra and Spasojević-Kalimanovska, Vesna",
year = "2019",
abstract = "Opstruktivna  apneja  u  snu  (OSA)  je  hronično  progresivno  oboljenje  sa  visokom prevalencom  u  populaciji  koje,  bez  pravovremene  dijagnoze  i  terapije,  može  dovesti  do značajnih posledica po kvalitet života pacijenata. OSA je čest komorbiditet  kod pacijenata sa metaboličkim sindromom (MS) i kardiovaskularnim bolestima (KVB) i predstavlja važan faktor rizika za nastanak ovih oboljenja, a prisustvo nelečenog, teškog oblika OSA povezano je sa porastom ukupnog i mortaliteta usled koronarnih događaja. Brojne studije su ukazale na vezu između MS i OSA, te je ovaj fenomen opisan kao poseban poremećaj - sindrom Z. Istraživanje uzročno-posledične veze između OSA i KVB je u velikoj meri otežano kompleksnom prirodom samog  oboljenja.  Smatra  se  da  je  kardiometabolički  rizik  u  OSA udružen  sa  arterijskom hipertenzijom,   insulinskom   rezistencijom,   endotelnom   disfunkcijom,   inflamacijom, dislipidemijom  i  oksidativnim  stresom.  Lečenje  OSA  se  danas  najefikasnije  sprovodi neinvazivnom  ventilacijom,  pomoću  uređaja  koji  obezbeđuje  pozitivan  pritisak  u  gornjim disajnim putevima (eng. continuous  positive  airway  pressure, CPAP) i na taj način sprečava pojavu  apneja  tokom  spavanja.  Rezultati  kliničkih  studija  su  pokazali  da  CPAP  terapija značajno  poboljšava  hemodinamske  parametre,  reguliše  hipertenziju,  povećava  osetljivost  na insulin i koriguje dislipidemiju. Buduća istraživanja bi trebalo da rasvetle da li je apneja u snu faktor rizika za KVB per  se ili je ta veza posledica šireg patofiziološkog procesa, čiji je deo i OSA., Obstructive sleep apnea (OSA) is a chronic, progressive disorder with a high prevalence in the population. Without timely diagnosis and therapy OSA can significantly affect the quality of life of the patients. OSA is a common co-morbidity in patients with metabolic syndrome (MS) and cardiovascular disease (CVD) and is an important risk factor for their development. The presence of untreated, severe OSA is associated with an increase in total and cardiovascular mortality. Numerous studies have pointed to the relationship between MS and OSA, and this phenomenon  was  described  as  syndrome  Z.  Investigation  of  the  causal relationship between OSA  and  CVD  has  been  greatly  confounded  by  the  complex  nature  of  the  disease  itself. Cardiometabolic  risk  in  OSA  is  associated  with  arterial  hypertension,  insulin  resistance, endothelial  dysfunction,  inflammation,  dyslipidemia,  and  oxidative  stress.  The  treatment  of OSA is now most effectively performed by continuous positive airway pressure (CPAP), a type of  non-invasive  ventilation  which  prevents  the  onset  of  sleep  apnea.  The  results  of  clinical studies  have  shown  that  CPAP  therapy  significantly  improves  haemodynamic  parameters, regulates  hypertension,  increases  insulin  sensitivity,  and  corrects  dyslipidemia.  Future investigations  should  clarify  whether  sleep  apnea  is  a  risk  factor  for  CVD per  se or is a consequence of a broader pathophysiological process, of which OSA is part.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Opstruktivna apneja u snu i kardiometabolički rizik, Obstructive sleep apnea and cardiometabolic risk",
volume = "69",
number = "3",
pages = "153-164",
doi = "10.5937/arhfarm1903153"
}
Vekić, J., Jelić-Ivanović, Z., Zeljković, A., Stefanović, A.,& Spasojević-Kalimanovska, V.. (2019). Opstruktivna apneja u snu i kardiometabolički rizik. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 69(3), 153-164.
https://doi.org/10.5937/arhfarm1903153
Vekić J, Jelić-Ivanović Z, Zeljković A, Stefanović A, Spasojević-Kalimanovska V. Opstruktivna apneja u snu i kardiometabolički rizik. in Arhiv za farmaciju. 2019;69(3):153-164.
doi:10.5937/arhfarm1903153 .
Vekić, Jelena, Jelić-Ivanović, Zorana, Zeljković, Aleksandra, Stefanović, Aleksandra, Spasojević-Kalimanovska, Vesna, "Opstruktivna apneja u snu i kardiometabolički rizik" in Arhiv za farmaciju, 69, no. 3 (2019):153-164,
https://doi.org/10.5937/arhfarm1903153 . .

Obesity and dyslipidemia

Vekić, Jelena; Zeljković, Aleksandra; Stefanović, Aleksandra; Jelić-Ivanović, Zorana; Spasojević-Kalimanovska, Vesna

(W B Saunders Co-Elsevier Inc, Philadelphia, 2019)

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3349
AB  - Obesity, a pandemic of the modern world, is intimately associated with dyslipidemia, which is mainly driven by the effects of insulin resistance and pro-inflammatory adipokines. However, recent evidence suggests that obesity-induced dyslipidemia is not a unique pathophysiological entity, but rather has distinct characteristics depending on many individual factors. In line with that, in a subgroup of metabolically healthy obese (MHO) individuals, dyslipidemia is less prominent or even absent. In this review, we will address the main characteristics of dyslipidemia and mechanisms that induce its development in obesity. The fields, which should be further investigated to expand our knowledge on obesity-related dyslipidemia and potentially yield new strategies for prevention and management of cardiometabolic risk, will be highlighted. Also, we will discuss recent findings on novel lipid biomarkers in obesity, in particular proprotein convertase subtilisin/kexin type 9 (PCSK9), as the key molecule that regulates metabolism of low-density lipoproteins (LDL), and sphingosine-1-phosphate (S1P), as one of the most important mediators of high-density lipoprotein (HDL) partides function. Special attention will be given to microRNAs and their potential use as biomarkers of obesity-associated dyslipidemia.
PB  - W B Saunders Co-Elsevier Inc, Philadelphia
T2  - Metabolism-Clinical and Experimental
T1  - Obesity and dyslipidemia
VL  - 92
SP  - 71
EP  - 81
DO  - 10.1016/j.metabol.2018.11.005
ER  - 
@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna",
year = "2019",
abstract = "Obesity, a pandemic of the modern world, is intimately associated with dyslipidemia, which is mainly driven by the effects of insulin resistance and pro-inflammatory adipokines. However, recent evidence suggests that obesity-induced dyslipidemia is not a unique pathophysiological entity, but rather has distinct characteristics depending on many individual factors. In line with that, in a subgroup of metabolically healthy obese (MHO) individuals, dyslipidemia is less prominent or even absent. In this review, we will address the main characteristics of dyslipidemia and mechanisms that induce its development in obesity. The fields, which should be further investigated to expand our knowledge on obesity-related dyslipidemia and potentially yield new strategies for prevention and management of cardiometabolic risk, will be highlighted. Also, we will discuss recent findings on novel lipid biomarkers in obesity, in particular proprotein convertase subtilisin/kexin type 9 (PCSK9), as the key molecule that regulates metabolism of low-density lipoproteins (LDL), and sphingosine-1-phosphate (S1P), as one of the most important mediators of high-density lipoprotein (HDL) partides function. Special attention will be given to microRNAs and their potential use as biomarkers of obesity-associated dyslipidemia.",
publisher = "W B Saunders Co-Elsevier Inc, Philadelphia",
journal = "Metabolism-Clinical and Experimental",
title = "Obesity and dyslipidemia",
volume = "92",
pages = "71-81",
doi = "10.1016/j.metabol.2018.11.005"
}
Vekić, J., Zeljković, A., Stefanović, A., Jelić-Ivanović, Z.,& Spasojević-Kalimanovska, V.. (2019). Obesity and dyslipidemia. in Metabolism-Clinical and Experimental
W B Saunders Co-Elsevier Inc, Philadelphia., 92, 71-81.
https://doi.org/10.1016/j.metabol.2018.11.005
Vekić J, Zeljković A, Stefanović A, Jelić-Ivanović Z, Spasojević-Kalimanovska V. Obesity and dyslipidemia. in Metabolism-Clinical and Experimental. 2019;92:71-81.
doi:10.1016/j.metabol.2018.11.005 .
Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, "Obesity and dyslipidemia" in Metabolism-Clinical and Experimental, 92 (2019):71-81,
https://doi.org/10.1016/j.metabol.2018.11.005 . .
16
336
114
306

Markers of Oxidative Stress and Endothelial Dysfunction Predict Haemodialysis Patients Survival

Šuvakov, Sonja; Jerotić, D; Damjanović, Tatjana; Milić, N; Pekmezović, T; Đukić, Tatjana; Jelić-Ivanović, Zorana; Savić-Radojević, Ana; Pljesa-Ercegovac, Marija; Matić, Marija; McClements, L; Dimković, Nada; Garović, V.D; Albright, R.C; Simić, Tatjana

(S. Karger AG, 2019)

TY  - JOUR
AU  - Šuvakov, Sonja
AU  - Jerotić, D
AU  - Damjanović, Tatjana
AU  - Milić, N
AU  - Pekmezović, T
AU  - Đukić, Tatjana
AU  - Jelić-Ivanović, Zorana
AU  - Savić-Radojević, Ana
AU  - Pljesa-Ercegovac, Marija
AU  - Matić, Marija
AU  - McClements, L
AU  - Dimković, Nada
AU  - Garović, V.D
AU  - Albright, R.C
AU  - Simić, Tatjana
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3277
AB  - Introduction: Overall survival of patients with end-stage renal disease (ESRD) remains poor. Oxidative stress is one of the major risk factors associated with mortality in this patient group. As glutathione S-transferases (GST) are well-established antioxidants, we hypothesized that a model including GST gene polymorphisms, oxidative damage byproducts and cell adhesion markers has a prognostic role in ESRD patient survival. Methods: A prospective study of 199 patients with ESRD on haemodialysis was conducted. GST genotype, oxidative stress byproducts and cell adhesion molecules were measured in plasma. Multivariate Cox regression and Kaplan-Meier survival analyses were performed to test the predictive ability of these parameters in the 8-year follow-up period. Results: GSTM1-null genotype was associated with significantly shorter overall (HR 1.6, p = 0.018) and cardiovascular-specific (HR 2.1, p = 0.010) survival. Oxidative stress byproducts (advanced oxidation protein products [AOPP], prooxidant-antioxidant balance [PAB], malondialdehyde [MDA]) and cell adhesion molecules (soluble vascular cell adhesion molecule-1 [sVCAM-1] and soluble intercellular adhesion molecule-1 [sICAM-1]) demonstrated a significant predictive role in terms of overall and cardiovascular survival. When 6 biomarkers (GSTM1 genotype, high AOPP/PAB/MDA/-sVCAM-1/sICAM-1) were combined into a scoring model, a significantly shorter overall and cardiovascular survival was observed for patients with the highest score (p  lt  0.001). Conclusion: We identified a novel panel of biomarkers that can be utilized in predicting survival in ESRD patients. This biomarker signature could enable better monitoring of patients and stratification into appropriate treatment groups.
PB  - S. Karger AG
T2  - American Journal of Nephrology
T1  - Markers of Oxidative Stress and Endothelial Dysfunction Predict Haemodialysis Patients Survival
DO  - 10.1159/000501300
ER  - 
@article{
author = "Šuvakov, Sonja and Jerotić, D and Damjanović, Tatjana and Milić, N and Pekmezović, T and Đukić, Tatjana and Jelić-Ivanović, Zorana and Savić-Radojević, Ana and Pljesa-Ercegovac, Marija and Matić, Marija and McClements, L and Dimković, Nada and Garović, V.D and Albright, R.C and Simić, Tatjana",
year = "2019",
abstract = "Introduction: Overall survival of patients with end-stage renal disease (ESRD) remains poor. Oxidative stress is one of the major risk factors associated with mortality in this patient group. As glutathione S-transferases (GST) are well-established antioxidants, we hypothesized that a model including GST gene polymorphisms, oxidative damage byproducts and cell adhesion markers has a prognostic role in ESRD patient survival. Methods: A prospective study of 199 patients with ESRD on haemodialysis was conducted. GST genotype, oxidative stress byproducts and cell adhesion molecules were measured in plasma. Multivariate Cox regression and Kaplan-Meier survival analyses were performed to test the predictive ability of these parameters in the 8-year follow-up period. Results: GSTM1-null genotype was associated with significantly shorter overall (HR 1.6, p = 0.018) and cardiovascular-specific (HR 2.1, p = 0.010) survival. Oxidative stress byproducts (advanced oxidation protein products [AOPP], prooxidant-antioxidant balance [PAB], malondialdehyde [MDA]) and cell adhesion molecules (soluble vascular cell adhesion molecule-1 [sVCAM-1] and soluble intercellular adhesion molecule-1 [sICAM-1]) demonstrated a significant predictive role in terms of overall and cardiovascular survival. When 6 biomarkers (GSTM1 genotype, high AOPP/PAB/MDA/-sVCAM-1/sICAM-1) were combined into a scoring model, a significantly shorter overall and cardiovascular survival was observed for patients with the highest score (p  lt  0.001). Conclusion: We identified a novel panel of biomarkers that can be utilized in predicting survival in ESRD patients. This biomarker signature could enable better monitoring of patients and stratification into appropriate treatment groups.",
publisher = "S. Karger AG",
journal = "American Journal of Nephrology",
title = "Markers of Oxidative Stress and Endothelial Dysfunction Predict Haemodialysis Patients Survival",
doi = "10.1159/000501300"
}
Šuvakov, S., Jerotić, D., Damjanović, T., Milić, N., Pekmezović, T., Đukić, T., Jelić-Ivanović, Z., Savić-Radojević, A., Pljesa-Ercegovac, M., Matić, M., McClements, L., Dimković, N., Garović, V.D, Albright, R.C,& Simić, T.. (2019). Markers of Oxidative Stress and Endothelial Dysfunction Predict Haemodialysis Patients Survival. in American Journal of Nephrology
S. Karger AG..
https://doi.org/10.1159/000501300
Šuvakov S, Jerotić D, Damjanović T, Milić N, Pekmezović T, Đukić T, Jelić-Ivanović Z, Savić-Radojević A, Pljesa-Ercegovac M, Matić M, McClements L, Dimković N, Garović V, Albright R, Simić T. Markers of Oxidative Stress and Endothelial Dysfunction Predict Haemodialysis Patients Survival. in American Journal of Nephrology. 2019;.
doi:10.1159/000501300 .
Šuvakov, Sonja, Jerotić, D, Damjanović, Tatjana, Milić, N, Pekmezović, T, Đukić, Tatjana, Jelić-Ivanović, Zorana, Savić-Radojević, Ana, Pljesa-Ercegovac, Marija, Matić, Marija, McClements, L, Dimković, Nada, Garović, V.D, Albright, R.C, Simić, Tatjana, "Markers of Oxidative Stress and Endothelial Dysfunction Predict Haemodialysis Patients Survival" in American Journal of Nephrology (2019),
https://doi.org/10.1159/000501300 . .
4
19
10
17

Preanalytical and analytical challenges in gas chromatographic determination of cholesterol synthesis and absorption markers

Gojković, Tamara; Vladimirov, Sandra; Spasojević-Kalimanovska, Vesna; Zeljković, Aleksandra; Vekić, Jelena; Arsenijević, Jelena; Đuričić, Ivana; Šobajić, Slađana; Jelić-Ivanović, Zorana

(Elsevier Science BV, Amsterdam, 2018)

TY  - JOUR
AU  - Gojković, Tamara
AU  - Vladimirov, Sandra
AU  - Spasojević-Kalimanovska, Vesna
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Arsenijević, Jelena
AU  - Đuričić, Ivana
AU  - Šobajić, Slađana
AU  - Jelić-Ivanović, Zorana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3185
AB  - Introduction: Cholesterol homeostasis disruption contributes to the development of different pathologies. Non cholesterol sterols (NCSs) serve as cholesterol synthesis markers (desmosterol and lathosterol), and cholesterol absorption surrogate markers (campesterol, stigmasterol and beta-sitosterol). The study aimed to resolve certain new pre-analytical and analytical problems and ensure a reliable and validated method. Materials and methods: Method optimization, validation and stability studies were executed in human serum and plasma. Freeze-thaw cycles were done with and without antioxidant. Gas chromatography-mass spectrometer (GC-MS) was used for NCSs confirmation and plasticizer identification, while GC-flame ionization detector (GC-FID) was used for NCSs quantitation. Results: Infra-and inter-assay variabilities for all NCSs were 2.75-9.55% and 5.80-7.75% for plasma and 3.10-5.72% and 3.05-10.92% for serum, respectively. Recovery studies showed satisfactory percentage errors for all NCSs: 93.4-105.7% in plasma and 87.5-106.9 in serum. Derivatized samples were stable up to 7 days at 20 degrees C and derivatization yield was affected by presence of plasticizers. Fatty acid amids were identified as interfering plastic leachates. Statistically different NCSs concentrations were observed after the 1st freeze-thaw cycle, in antioxidant-free samples, and after the 4th cycle in antioxidant-enriched samples. Conclusions: All of the in-house procedures proved to be useful for minimizing the preanalytical and analytical variations, as proven by the validation results.
PB  - Elsevier Science BV, Amsterdam
T2  - Clinica Chimica Acta
T1  - Preanalytical and analytical challenges in gas chromatographic determination of cholesterol synthesis and absorption markers
VL  - 478
SP  - 74
EP  - 81
DO  - 10.1016/j.cca.2017.12.032
ER  - 
@article{
author = "Gojković, Tamara and Vladimirov, Sandra and Spasojević-Kalimanovska, Vesna and Zeljković, Aleksandra and Vekić, Jelena and Arsenijević, Jelena and Đuričić, Ivana and Šobajić, Slađana and Jelić-Ivanović, Zorana",
year = "2018",
abstract = "Introduction: Cholesterol homeostasis disruption contributes to the development of different pathologies. Non cholesterol sterols (NCSs) serve as cholesterol synthesis markers (desmosterol and lathosterol), and cholesterol absorption surrogate markers (campesterol, stigmasterol and beta-sitosterol). The study aimed to resolve certain new pre-analytical and analytical problems and ensure a reliable and validated method. Materials and methods: Method optimization, validation and stability studies were executed in human serum and plasma. Freeze-thaw cycles were done with and without antioxidant. Gas chromatography-mass spectrometer (GC-MS) was used for NCSs confirmation and plasticizer identification, while GC-flame ionization detector (GC-FID) was used for NCSs quantitation. Results: Infra-and inter-assay variabilities for all NCSs were 2.75-9.55% and 5.80-7.75% for plasma and 3.10-5.72% and 3.05-10.92% for serum, respectively. Recovery studies showed satisfactory percentage errors for all NCSs: 93.4-105.7% in plasma and 87.5-106.9 in serum. Derivatized samples were stable up to 7 days at 20 degrees C and derivatization yield was affected by presence of plasticizers. Fatty acid amids were identified as interfering plastic leachates. Statistically different NCSs concentrations were observed after the 1st freeze-thaw cycle, in antioxidant-free samples, and after the 4th cycle in antioxidant-enriched samples. Conclusions: All of the in-house procedures proved to be useful for minimizing the preanalytical and analytical variations, as proven by the validation results.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "Clinica Chimica Acta",
title = "Preanalytical and analytical challenges in gas chromatographic determination of cholesterol synthesis and absorption markers",
volume = "478",
pages = "74-81",
doi = "10.1016/j.cca.2017.12.032"
}
Gojković, T., Vladimirov, S., Spasojević-Kalimanovska, V., Zeljković, A., Vekić, J., Arsenijević, J., Đuričić, I., Šobajić, S.,& Jelić-Ivanović, Z.. (2018). Preanalytical and analytical challenges in gas chromatographic determination of cholesterol synthesis and absorption markers. in Clinica Chimica Acta
Elsevier Science BV, Amsterdam., 478, 74-81.
https://doi.org/10.1016/j.cca.2017.12.032
Gojković T, Vladimirov S, Spasojević-Kalimanovska V, Zeljković A, Vekić J, Arsenijević J, Đuričić I, Šobajić S, Jelić-Ivanović Z. Preanalytical and analytical challenges in gas chromatographic determination of cholesterol synthesis and absorption markers. in Clinica Chimica Acta. 2018;478:74-81.
doi:10.1016/j.cca.2017.12.032 .
Gojković, Tamara, Vladimirov, Sandra, Spasojević-Kalimanovska, Vesna, Zeljković, Aleksandra, Vekić, Jelena, Arsenijević, Jelena, Đuričić, Ivana, Šobajić, Slađana, Jelić-Ivanović, Zorana, "Preanalytical and analytical challenges in gas chromatographic determination of cholesterol synthesis and absorption markers" in Clinica Chimica Acta, 478 (2018):74-81,
https://doi.org/10.1016/j.cca.2017.12.032 . .
6
4
5

The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet

Bogavac-Stanojević, Nataša; Kotur-Stevuljević, Jelena; Cerne, Darko; Zupan, Janja; Marc, Janja; Vujić, Zorica; Crevar-Sakač, Milkica; Sopić, Miron; Munjas, Jelena; Radenković, Miroslav; Jelić-Ivanović, Zorana

(Taylor & Francis Ltd, Abingdon, 2018)

TY  - JOUR
AU  - Bogavac-Stanojević, Nataša
AU  - Kotur-Stevuljević, Jelena
AU  - Cerne, Darko
AU  - Zupan, Janja
AU  - Marc, Janja
AU  - Vujić, Zorica
AU  - Crevar-Sakač, Milkica
AU  - Sopić, Miron
AU  - Munjas, Jelena
AU  - Radenković, Miroslav
AU  - Jelić-Ivanović, Zorana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3189
AB  - Context: Polyphenols and flavonoids in artichoke leaf tincture (ALT) protect cells against oxidative damage. Objectives: We examined ALT effects on deoxyribonucleic acid (DNA) damage and lipid profiles in rat plasma and gene expression in rat aorta [haemeoxygenase-1 (HO1), haemeoxygenase-2 (HO2), NADPH oxidase 4 (NOX-4), monocyte chemoattractant protein-1 (MCP-1) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2)]. Materials and methods: Eighteen male Wistar albino rats were divided into three groups (n=6/group): The control group (CG) was fed with standard pellet chow for 11 weeks; the AD group was fed for a similar period of time with pellet chow supplemented with 2% cholesterol, 3% sunflower oil and 1% sodium cholate. The ADA group was fed with pellet chow (for 1 week), the atherogenic diet (see above) for the following 4 weeks and then with ALT (0.1 mL/kg body weight) and atherogenic diet for 6 weeks. According to HPLC analysis, the isolated main compounds in ALT were chlorogenic acid, caffeic acid, isoquercitrin and rutin. Results: Normalized HO-1 [0.11 (0.04-0.24)] and MCP-1 [0.29 (0.21-0.47)] mRNA levels and DNA scores [12.50 (4.50-36.50)] were significantly lower in the ADA group than in the AD group [0.84 (0.35-2.51)], p = 0.021 for HO-1 [0.85 (0.61-3.45)], p = 0.047 for MCP-1 and [176.5 (66.50-221.25)], p = 0.020 for DNA scores. HO-1 mRNA was lower in the ADA group than in the CG group [0.30 (0.21-0.71), p = 0.049]. Conclusions: Supplementation with ALT limited the effects of the atherogenic diet through reduced MCP-1 expression, thereby preventing oxidative damage.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Pharmaceutical Biology
T1  - The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet
VL  - 56
IS  - 1
SP  - 138
EP  - 144
DO  - 10.1080/13880209.2018.1434549
ER  - 
@article{
author = "Bogavac-Stanojević, Nataša and Kotur-Stevuljević, Jelena and Cerne, Darko and Zupan, Janja and Marc, Janja and Vujić, Zorica and Crevar-Sakač, Milkica and Sopić, Miron and Munjas, Jelena and Radenković, Miroslav and Jelić-Ivanović, Zorana",
year = "2018",
abstract = "Context: Polyphenols and flavonoids in artichoke leaf tincture (ALT) protect cells against oxidative damage. Objectives: We examined ALT effects on deoxyribonucleic acid (DNA) damage and lipid profiles in rat plasma and gene expression in rat aorta [haemeoxygenase-1 (HO1), haemeoxygenase-2 (HO2), NADPH oxidase 4 (NOX-4), monocyte chemoattractant protein-1 (MCP-1) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2)]. Materials and methods: Eighteen male Wistar albino rats were divided into three groups (n=6/group): The control group (CG) was fed with standard pellet chow for 11 weeks; the AD group was fed for a similar period of time with pellet chow supplemented with 2% cholesterol, 3% sunflower oil and 1% sodium cholate. The ADA group was fed with pellet chow (for 1 week), the atherogenic diet (see above) for the following 4 weeks and then with ALT (0.1 mL/kg body weight) and atherogenic diet for 6 weeks. According to HPLC analysis, the isolated main compounds in ALT were chlorogenic acid, caffeic acid, isoquercitrin and rutin. Results: Normalized HO-1 [0.11 (0.04-0.24)] and MCP-1 [0.29 (0.21-0.47)] mRNA levels and DNA scores [12.50 (4.50-36.50)] were significantly lower in the ADA group than in the AD group [0.84 (0.35-2.51)], p = 0.021 for HO-1 [0.85 (0.61-3.45)], p = 0.047 for MCP-1 and [176.5 (66.50-221.25)], p = 0.020 for DNA scores. HO-1 mRNA was lower in the ADA group than in the CG group [0.30 (0.21-0.71), p = 0.049]. Conclusions: Supplementation with ALT limited the effects of the atherogenic diet through reduced MCP-1 expression, thereby preventing oxidative damage.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Pharmaceutical Biology",
title = "The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet",
volume = "56",
number = "1",
pages = "138-144",
doi = "10.1080/13880209.2018.1434549"
}
Bogavac-Stanojević, N., Kotur-Stevuljević, J., Cerne, D., Zupan, J., Marc, J., Vujić, Z., Crevar-Sakač, M., Sopić, M., Munjas, J., Radenković, M.,& Jelić-Ivanović, Z.. (2018). The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet. in Pharmaceutical Biology
Taylor & Francis Ltd, Abingdon., 56(1), 138-144.
https://doi.org/10.1080/13880209.2018.1434549
Bogavac-Stanojević N, Kotur-Stevuljević J, Cerne D, Zupan J, Marc J, Vujić Z, Crevar-Sakač M, Sopić M, Munjas J, Radenković M, Jelić-Ivanović Z. The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet. in Pharmaceutical Biology. 2018;56(1):138-144.
doi:10.1080/13880209.2018.1434549 .
Bogavac-Stanojević, Nataša, Kotur-Stevuljević, Jelena, Cerne, Darko, Zupan, Janja, Marc, Janja, Vujić, Zorica, Crevar-Sakač, Milkica, Sopić, Miron, Munjas, Jelena, Radenković, Miroslav, Jelić-Ivanović, Zorana, "The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet" in Pharmaceutical Biology, 56, no. 1 (2018):138-144,
https://doi.org/10.1080/13880209.2018.1434549 . .
14
5
14

Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease

Ninić, Ana; Sopić, Miron; Munjas, Jelena; Spasojević-Kalimanovska, Vesna; Kotur-Stevuljević, Jelena; Bogavac-Stanojević, Nataša; Ivanišević, Jasmina; Simić-Ogrizović, Sanja; Kravljaca, Milica; Jelić-Ivanović, Zorana

(Galenos Yayincilik, Findikzade, 2018)

TY  - JOUR
AU  - Ninić, Ana
AU  - Sopić, Miron
AU  - Munjas, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kotur-Stevuljević, Jelena
AU  - Bogavac-Stanojević, Nataša
AU  - Ivanišević, Jasmina
AU  - Simić-Ogrizović, Sanja
AU  - Kravljaca, Milica
AU  - Jelić-Ivanović, Zorana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3060
AB  - Background: Chronic renal failure, particularly end-stage renal disease, is a serious health problem associated with a high mortality rate. Uremic syndrome leads to increased oxidative stress, inflammation, and dyslipidemia. Aims: To examine superoxide dismutase isoenzyme gene expression in peripheral blood mononuclear cells of patients on hemodialysis and to determine the associations between superoxide dismutase isoenzyme gene expression, oxidative stress, and non-enzymatic antioxidative protection. Study Design: Case control study. Methods: This study included 33 patients on hemodialysis (age, 55.33 +/- 15.31 years old) and 33 apparently healthy controls (age, 45.37 +/- 8.92 years old). Superoxide dismutase isoenzyme messenger ribonucleic acid levels were determined by real-time polymerase chain reaction. General biochemical parameters, high sensitivity C-reactive protein, total antioxidant status, thiobarbituric acid-reactive substances, and the superoxide anion radical were also determined. Results: Normalized Cu/Zn superoxide dismutase and Mn superoxide dismutase messenger ribonucleic acid levels were significantly higher in patients than controls (p lt 0.001 and p=0.011). A significant negative correlation was detected between normalized Cu/Zn superoxide dismutase messenger ribonucleic acid levels and total protein total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and total antioxidant status. Normalized Mn superoxide dismutase messenger ribonucleic acid levels were negatively correlated with total protein and total antioxidant status. A multiple regression analysis revealed independent associations between total antioxidant status and normalized Cu/Zn superoxide dismutase (p=0.038) and between total antioxidant status and normalized Mn superoxide dismutase messenger ribonucleic acid levels (p=0.038 and p=0.018, respectively). Conclusion: The superoxide dismutase isoenzyme gene is expressed at a higher rate in patients with end-stage renal failure, probably due to increased oxidative stress and attenuated antioxidative defense. The plasma total antioxidant status is an independent predictor of normalized superoxide dismutase isoenzyme messenger ribonucleic acid levels.
PB  - Galenos Yayincilik, Findikzade
T2  - Balkan Medical Journal
T1  - Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease
VL  - 35
IS  - 6
SP  - 431
EP  - 436
DO  - 10.4274/balkanmedj.2018.0170
ER  - 
@article{
author = "Ninić, Ana and Sopić, Miron and Munjas, Jelena and Spasojević-Kalimanovska, Vesna and Kotur-Stevuljević, Jelena and Bogavac-Stanojević, Nataša and Ivanišević, Jasmina and Simić-Ogrizović, Sanja and Kravljaca, Milica and Jelić-Ivanović, Zorana",
year = "2018",
abstract = "Background: Chronic renal failure, particularly end-stage renal disease, is a serious health problem associated with a high mortality rate. Uremic syndrome leads to increased oxidative stress, inflammation, and dyslipidemia. Aims: To examine superoxide dismutase isoenzyme gene expression in peripheral blood mononuclear cells of patients on hemodialysis and to determine the associations between superoxide dismutase isoenzyme gene expression, oxidative stress, and non-enzymatic antioxidative protection. Study Design: Case control study. Methods: This study included 33 patients on hemodialysis (age, 55.33 +/- 15.31 years old) and 33 apparently healthy controls (age, 45.37 +/- 8.92 years old). Superoxide dismutase isoenzyme messenger ribonucleic acid levels were determined by real-time polymerase chain reaction. General biochemical parameters, high sensitivity C-reactive protein, total antioxidant status, thiobarbituric acid-reactive substances, and the superoxide anion radical were also determined. Results: Normalized Cu/Zn superoxide dismutase and Mn superoxide dismutase messenger ribonucleic acid levels were significantly higher in patients than controls (p lt 0.001 and p=0.011). A significant negative correlation was detected between normalized Cu/Zn superoxide dismutase messenger ribonucleic acid levels and total protein total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and total antioxidant status. Normalized Mn superoxide dismutase messenger ribonucleic acid levels were negatively correlated with total protein and total antioxidant status. A multiple regression analysis revealed independent associations between total antioxidant status and normalized Cu/Zn superoxide dismutase (p=0.038) and between total antioxidant status and normalized Mn superoxide dismutase messenger ribonucleic acid levels (p=0.038 and p=0.018, respectively). Conclusion: The superoxide dismutase isoenzyme gene is expressed at a higher rate in patients with end-stage renal failure, probably due to increased oxidative stress and attenuated antioxidative defense. The plasma total antioxidant status is an independent predictor of normalized superoxide dismutase isoenzyme messenger ribonucleic acid levels.",
publisher = "Galenos Yayincilik, Findikzade",
journal = "Balkan Medical Journal",
title = "Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease",
volume = "35",
number = "6",
pages = "431-436",
doi = "10.4274/balkanmedj.2018.0170"
}
Ninić, A., Sopić, M., Munjas, J., Spasojević-Kalimanovska, V., Kotur-Stevuljević, J., Bogavac-Stanojević, N., Ivanišević, J., Simić-Ogrizović, S., Kravljaca, M.,& Jelić-Ivanović, Z.. (2018). Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease. in Balkan Medical Journal
Galenos Yayincilik, Findikzade., 35(6), 431-436.
https://doi.org/10.4274/balkanmedj.2018.0170
Ninić A, Sopić M, Munjas J, Spasojević-Kalimanovska V, Kotur-Stevuljević J, Bogavac-Stanojević N, Ivanišević J, Simić-Ogrizović S, Kravljaca M, Jelić-Ivanović Z. Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease. in Balkan Medical Journal. 2018;35(6):431-436.
doi:10.4274/balkanmedj.2018.0170 .
Ninić, Ana, Sopić, Miron, Munjas, Jelena, Spasojević-Kalimanovska, Vesna, Kotur-Stevuljević, Jelena, Bogavac-Stanojević, Nataša, Ivanišević, Jasmina, Simić-Ogrizović, Sanja, Kravljaca, Milica, Jelić-Ivanović, Zorana, "Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease" in Balkan Medical Journal, 35, no. 6 (2018):431-436,
https://doi.org/10.4274/balkanmedj.2018.0170 . .
9
6
9

Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy

Ninić, Ana; Spasojević-Kalimanovska, Vesna; Sopić, Miron; Munjas, Jelena; Bogavac-Stanojević, Nataša; Jelić-Ivanović, Zorana; Kotur-Stevuljević, Jelena; Spasić, Slavica; Crevar-Sakač, Milkica; Milenković, Marina; Vujić, Zorica

(Natl Inst Science Communication-Niscair, New Delhi, 2018)

TY  - JOUR
AU  - Ninić, Ana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Sopić, Miron
AU  - Munjas, Jelena
AU  - Bogavac-Stanojević, Nataša
AU  - Jelić-Ivanović, Zorana
AU  - Kotur-Stevuljević, Jelena
AU  - Spasić, Slavica
AU  - Crevar-Sakač, Milkica
AU  - Milenković, Marina
AU  - Vujić, Zorica
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3054
AB  - Paraoxonases isoenzymes, PON1, PON2 and PON3, have important antioxidative and anti-inflammatory properties in blood and cells. They prevent oxidation of low and high density lipoprotein particles, foam cells formation and development of atherosclerosis. The authors investigated effects of high fat diet and atorvastatin therapy on paraoxonases gene expression levels and distribution in different rat organs. Liver, white adipose tissue (WAT) and aorta were taken from young male Wistar rats that were fed with normal diet (ND), atherogenic diet (AD) and atherogenic diet with 1.14 mg of atorvastatin per kg (ADA). Messenger RNA (mRNA) relative levels of paraoxonase 1 (PON1), paraoxonase 2 (PON2) and paraoxonase 3 (PON3) were measured in rat organs using real-time polymerase chain reaction (PCR). PON1 mRNA expression levels were down-regulated in ADA compared to AD group. ND group had significantly lower PON2 mRNA expression than AD group. PON1 mRNA expression levels were higher in liver than in aorta in group of rats on ND, AD and ADA. PON2 mRNA expression was higher in WAT than in aorta only in ADA group of rats. PON2 and PON3 were significantly higher than PON1 in aorta of rats on each ND, AD or ADA.
PB  - Natl Inst Science Communication-Niscair, New Delhi
T2  - Indian Journal of Biotechnology
T1  - Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy
VL  - 17
IS  - 2
SP  - 217
EP  - 223
UR  - https://hdl.handle.net/21.15107/rcub_farfar_3054
ER  - 
@article{
author = "Ninić, Ana and Spasojević-Kalimanovska, Vesna and Sopić, Miron and Munjas, Jelena and Bogavac-Stanojević, Nataša and Jelić-Ivanović, Zorana and Kotur-Stevuljević, Jelena and Spasić, Slavica and Crevar-Sakač, Milkica and Milenković, Marina and Vujić, Zorica",
year = "2018",
abstract = "Paraoxonases isoenzymes, PON1, PON2 and PON3, have important antioxidative and anti-inflammatory properties in blood and cells. They prevent oxidation of low and high density lipoprotein particles, foam cells formation and development of atherosclerosis. The authors investigated effects of high fat diet and atorvastatin therapy on paraoxonases gene expression levels and distribution in different rat organs. Liver, white adipose tissue (WAT) and aorta were taken from young male Wistar rats that were fed with normal diet (ND), atherogenic diet (AD) and atherogenic diet with 1.14 mg of atorvastatin per kg (ADA). Messenger RNA (mRNA) relative levels of paraoxonase 1 (PON1), paraoxonase 2 (PON2) and paraoxonase 3 (PON3) were measured in rat organs using real-time polymerase chain reaction (PCR). PON1 mRNA expression levels were down-regulated in ADA compared to AD group. ND group had significantly lower PON2 mRNA expression than AD group. PON1 mRNA expression levels were higher in liver than in aorta in group of rats on ND, AD and ADA. PON2 mRNA expression was higher in WAT than in aorta only in ADA group of rats. PON2 and PON3 were significantly higher than PON1 in aorta of rats on each ND, AD or ADA.",
publisher = "Natl Inst Science Communication-Niscair, New Delhi",
journal = "Indian Journal of Biotechnology",
title = "Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy",
volume = "17",
number = "2",
pages = "217-223",
url = "https://hdl.handle.net/21.15107/rcub_farfar_3054"
}
Ninić, A., Spasojević-Kalimanovska, V., Sopić, M., Munjas, J., Bogavac-Stanojević, N., Jelić-Ivanović, Z., Kotur-Stevuljević, J., Spasić, S., Crevar-Sakač, M., Milenković, M.,& Vujić, Z.. (2018). Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy. in Indian Journal of Biotechnology
Natl Inst Science Communication-Niscair, New Delhi., 17(2), 217-223.
https://hdl.handle.net/21.15107/rcub_farfar_3054
Ninić A, Spasojević-Kalimanovska V, Sopić M, Munjas J, Bogavac-Stanojević N, Jelić-Ivanović Z, Kotur-Stevuljević J, Spasić S, Crevar-Sakač M, Milenković M, Vujić Z. Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy. in Indian Journal of Biotechnology. 2018;17(2):217-223.
https://hdl.handle.net/21.15107/rcub_farfar_3054 .
Ninić, Ana, Spasojević-Kalimanovska, Vesna, Sopić, Miron, Munjas, Jelena, Bogavac-Stanojević, Nataša, Jelić-Ivanović, Zorana, Kotur-Stevuljević, Jelena, Spasić, Slavica, Crevar-Sakač, Milkica, Milenković, Marina, Vujić, Zorica, "Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy" in Indian Journal of Biotechnology, 17, no. 2 (2018):217-223,
https://hdl.handle.net/21.15107/rcub_farfar_3054 .
1
1

Associations of lipoprotein subclasses and oxidative stress status in pulmonary and pulmonary plus extrapulmonary sarcoidosis

Ivanišević, Jasmina; Vekić, Jelena; Zeljković, Aleksandra; Stefanović, Aleksandra; Kotur-Stevuljević, Jelena; Spasojević-Kalimanovska, Vesna; Spasić, Slavica; Vučinić-Mihailović, Violeta; Videnović-Ivanov, Jelica; Jelić-Ivanović, Zorana

(Mattioli 1885, Fidenza, 2018)

TY  - JOUR
AU  - Ivanišević, Jasmina
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Kotur-Stevuljević, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Spasić, Slavica
AU  - Vučinić-Mihailović, Violeta
AU  - Videnović-Ivanov, Jelica
AU  - Jelić-Ivanović, Zorana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3078
AB  - Background: Sarcoidosis is an inflammatory disease with pulmonary and extrapulmonary manifestations. In such pathologic conditions, increased oxidative stress and rearrangement of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) may occur. Objective: This study evaluated association of oxidative stress and lipoprotein subclasses in severe forms of pulmonary and pulmonary plus extrapulmonary sarcoidosis. Methods: Lipid parameters, LDL and HDL subclass distributions, high-sensitivity C-reactive protein (hsCRP), serum amyloid A (SAA), paraoxonase 1 (PON1), malondialdehyde (MDA), total-oxidant status (TOS), sulfhydryl (SH) groups, pro-oxidant anti-oxidant balance (PAB) were determined in 77 patients (53 isolated pulmonary and 24 pulmonary plus extrapulmonary) and 139 controls. Results: Both pulmonary and extrapulmonary sarcoidosis patients had significantly higher levels of triglycerides and TOS (P lt 0.05) and more LDL II, LDL III, LDL IVA particles (P lt 0.01), but lower HDL size, SH groups (P lt 0.001), PON1 activity and less LDL I subclasses (P lt 0.05) than controls. In isolated pulmonary disease, HDL-cholesterol (P lt 0.01) was significantly lower whereas proportions of HDL 3a and PAB were significantly higher (P lt 0.05) when compared with the control group. PON1 was significantly higher in pulmonary than in combined pulmonary-extrapulmonary disease (P lt 0.05). In pulmonary sarcoidosis, TOS and PON1 correlated significantly with small-sized HDL particles (P lt 0.05). Conclusions: Both patient groups were characterized by adverse lipoprotein profile and elevated oxidative stress. In isolated pulmonary group significant associations of oxidative stress and HDL particles distribution was demonstrated. Pulmonary sarcoidosis was associated with higher PON1 activity and rearrangement of LDL particles did not depend on disease localization.
PB  - Mattioli 1885, Fidenza
T2  - Sarcoidosis Vasculitis and Diffuse Lung Diseases
T1  - Associations of lipoprotein subclasses and oxidative stress status in pulmonary and pulmonary plus extrapulmonary sarcoidosis
VL  - 35
IS  - 3
SP  - 198
EP  - 205
DO  - 10.36141/svdld.v35i3.6573
UR  - https://hdl.handle.net/21.15107/rcub_farfar_3078
ER  - 
@article{
author = "Ivanišević, Jasmina and Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Kotur-Stevuljević, Jelena and Spasojević-Kalimanovska, Vesna and Spasić, Slavica and Vučinić-Mihailović, Violeta and Videnović-Ivanov, Jelica and Jelić-Ivanović, Zorana",
year = "2018",
abstract = "Background: Sarcoidosis is an inflammatory disease with pulmonary and extrapulmonary manifestations. In such pathologic conditions, increased oxidative stress and rearrangement of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) may occur. Objective: This study evaluated association of oxidative stress and lipoprotein subclasses in severe forms of pulmonary and pulmonary plus extrapulmonary sarcoidosis. Methods: Lipid parameters, LDL and HDL subclass distributions, high-sensitivity C-reactive protein (hsCRP), serum amyloid A (SAA), paraoxonase 1 (PON1), malondialdehyde (MDA), total-oxidant status (TOS), sulfhydryl (SH) groups, pro-oxidant anti-oxidant balance (PAB) were determined in 77 patients (53 isolated pulmonary and 24 pulmonary plus extrapulmonary) and 139 controls. Results: Both pulmonary and extrapulmonary sarcoidosis patients had significantly higher levels of triglycerides and TOS (P lt 0.05) and more LDL II, LDL III, LDL IVA particles (P lt 0.01), but lower HDL size, SH groups (P lt 0.001), PON1 activity and less LDL I subclasses (P lt 0.05) than controls. In isolated pulmonary disease, HDL-cholesterol (P lt 0.01) was significantly lower whereas proportions of HDL 3a and PAB were significantly higher (P lt 0.05) when compared with the control group. PON1 was significantly higher in pulmonary than in combined pulmonary-extrapulmonary disease (P lt 0.05). In pulmonary sarcoidosis, TOS and PON1 correlated significantly with small-sized HDL particles (P lt 0.05). Conclusions: Both patient groups were characterized by adverse lipoprotein profile and elevated oxidative stress. In isolated pulmonary group significant associations of oxidative stress and HDL particles distribution was demonstrated. Pulmonary sarcoidosis was associated with higher PON1 activity and rearrangement of LDL particles did not depend on disease localization.",
publisher = "Mattioli 1885, Fidenza",
journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",
title = "Associations of lipoprotein subclasses and oxidative stress status in pulmonary and pulmonary plus extrapulmonary sarcoidosis",
volume = "35",
number = "3",
pages = "198-205",
doi = "10.36141/svdld.v35i3.6573",
url = "https://hdl.handle.net/21.15107/rcub_farfar_3078"
}
Ivanišević, J., Vekić, J., Zeljković, A., Stefanović, A., Kotur-Stevuljević, J., Spasojević-Kalimanovska, V., Spasić, S., Vučinić-Mihailović, V., Videnović-Ivanov, J.,& Jelić-Ivanović, Z.. (2018). Associations of lipoprotein subclasses and oxidative stress status in pulmonary and pulmonary plus extrapulmonary sarcoidosis. in Sarcoidosis Vasculitis and Diffuse Lung Diseases
Mattioli 1885, Fidenza., 35(3), 198-205.
https://doi.org/10.36141/svdld.v35i3.6573
https://hdl.handle.net/21.15107/rcub_farfar_3078
Ivanišević J, Vekić J, Zeljković A, Stefanović A, Kotur-Stevuljević J, Spasojević-Kalimanovska V, Spasić S, Vučinić-Mihailović V, Videnović-Ivanov J, Jelić-Ivanović Z. Associations of lipoprotein subclasses and oxidative stress status in pulmonary and pulmonary plus extrapulmonary sarcoidosis. in Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2018;35(3):198-205.
doi:10.36141/svdld.v35i3.6573
https://hdl.handle.net/21.15107/rcub_farfar_3078 .
Ivanišević, Jasmina, Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Kotur-Stevuljević, Jelena, Spasojević-Kalimanovska, Vesna, Spasić, Slavica, Vučinić-Mihailović, Violeta, Videnović-Ivanov, Jelica, Jelić-Ivanović, Zorana, "Associations of lipoprotein subclasses and oxidative stress status in pulmonary and pulmonary plus extrapulmonary sarcoidosis" in Sarcoidosis Vasculitis and Diffuse Lung Diseases, 35, no. 3 (2018):198-205,
https://doi.org/10.36141/svdld.v35i3.6573 .,
https://hdl.handle.net/21.15107/rcub_farfar_3078 .
4
4
4

Association of statin therapy with plasma fatty acids profile and lipoprotein-associated phospholipase A2 concentration

Gojković, Tamara; Vladimirov, Sandra; Spasojević-Kalimanovska, Vesna; Zeljković, Aleksandra; Vekić, Jelena; Miljković, Milica; Stefanović, Aleksandra; Kalimanovska-Oštrić, Dimitra; Đuričić, Ivana; Jelić-Ivanović, Zorana

(Elsevier Ireland Ltd, Clare, 2018)

TY  - CONF
AU  - Gojković, Tamara
AU  - Vladimirov, Sandra
AU  - Spasojević-Kalimanovska, Vesna
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Kalimanovska-Oštrić, Dimitra
AU  - Đuričić, Ivana
AU  - Jelić-Ivanović, Zorana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3071
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Association of statin therapy with plasma fatty acids profile and lipoprotein-associated phospholipase A2 concentration
VL  - 275
SP  - e60
EP  - e60
DO  - 10.1016/j.atherosclerosis.2018.06.164
ER  - 
@conference{
author = "Gojković, Tamara and Vladimirov, Sandra and Spasojević-Kalimanovska, Vesna and Zeljković, Aleksandra and Vekić, Jelena and Miljković, Milica and Stefanović, Aleksandra and Kalimanovska-Oštrić, Dimitra and Đuričić, Ivana and Jelić-Ivanović, Zorana",
year = "2018",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Association of statin therapy with plasma fatty acids profile and lipoprotein-associated phospholipase A2 concentration",
volume = "275",
pages = "e60-e60",
doi = "10.1016/j.atherosclerosis.2018.06.164"
}
Gojković, T., Vladimirov, S., Spasojević-Kalimanovska, V., Zeljković, A., Vekić, J., Miljković, M., Stefanović, A., Kalimanovska-Oštrić, D., Đuričić, I.,& Jelić-Ivanović, Z.. (2018). Association of statin therapy with plasma fatty acids profile and lipoprotein-associated phospholipase A2 concentration. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 275, e60-e60.
https://doi.org/10.1016/j.atherosclerosis.2018.06.164
Gojković T, Vladimirov S, Spasojević-Kalimanovska V, Zeljković A, Vekić J, Miljković M, Stefanović A, Kalimanovska-Oštrić D, Đuričić I, Jelić-Ivanović Z. Association of statin therapy with plasma fatty acids profile and lipoprotein-associated phospholipase A2 concentration. in Atherosclerosis. 2018;275:e60-e60.
doi:10.1016/j.atherosclerosis.2018.06.164 .
Gojković, Tamara, Vladimirov, Sandra, Spasojević-Kalimanovska, Vesna, Zeljković, Aleksandra, Vekić, Jelena, Miljković, Milica, Stefanović, Aleksandra, Kalimanovska-Oštrić, Dimitra, Đuričić, Ivana, Jelić-Ivanović, Zorana, "Association of statin therapy with plasma fatty acids profile and lipoprotein-associated phospholipase A2 concentration" in Atherosclerosis, 275 (2018):e60-e60,
https://doi.org/10.1016/j.atherosclerosis.2018.06.164 . .

Association of cholesterol homeostasis parameters with cardiovascular risk factors in healthy population

Vladimirov, Sandra; Gojković, Tamara; Zeljković, Aleksandra; Jelić-Ivanović, Zorana; Miljković, Milica; Bogavac-Stanojević, Nataša; Stepanović, Željka; Spasojević-Kalimanovska, Vesna

(Elsevier Ireland Ltd, Clare, 2018)

TY  - CONF
AU  - Vladimirov, Sandra
AU  - Gojković, Tamara
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Miljković, Milica
AU  - Bogavac-Stanojević, Nataša
AU  - Stepanović, Željka
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3073
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Association of cholesterol homeostasis parameters with cardiovascular risk factors in healthy population
VL  - 275
SP  - e86
EP  - e86
DO  - 10.1016/j.atherosclerosis.2018.06.238
ER  - 
@conference{
author = "Vladimirov, Sandra and Gojković, Tamara and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Miljković, Milica and Bogavac-Stanojević, Nataša and Stepanović, Željka and Spasojević-Kalimanovska, Vesna",
year = "2018",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Association of cholesterol homeostasis parameters with cardiovascular risk factors in healthy population",
volume = "275",
pages = "e86-e86",
doi = "10.1016/j.atherosclerosis.2018.06.238"
}
Vladimirov, S., Gojković, T., Zeljković, A., Jelić-Ivanović, Z., Miljković, M., Bogavac-Stanojević, N., Stepanović, Ž.,& Spasojević-Kalimanovska, V.. (2018). Association of cholesterol homeostasis parameters with cardiovascular risk factors in healthy population. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 275, e86-e86.
https://doi.org/10.1016/j.atherosclerosis.2018.06.238
Vladimirov S, Gojković T, Zeljković A, Jelić-Ivanović Z, Miljković M, Bogavac-Stanojević N, Stepanović Ž, Spasojević-Kalimanovska V. Association of cholesterol homeostasis parameters with cardiovascular risk factors in healthy population. in Atherosclerosis. 2018;275:e86-e86.
doi:10.1016/j.atherosclerosis.2018.06.238 .
Vladimirov, Sandra, Gojković, Tamara, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Miljković, Milica, Bogavac-Stanojević, Nataša, Stepanović, Željka, Spasojević-Kalimanovska, Vesna, "Association of cholesterol homeostasis parameters with cardiovascular risk factors in healthy population" in Atherosclerosis, 275 (2018):e86-e86,
https://doi.org/10.1016/j.atherosclerosis.2018.06.238 . .

Adipor1 polymorphism g.202940846g > c (rs7539542) is associated with higher cardiovascular risk in middle-aged population

Sopić, Miron; Mihajlović, Marija; Ninić, Ana; Bogavac-Stanojević, Nataša; Stepanović, Željka; Vekić, Jelena; Zeljković, Aleksandra; Janać, Jelena; Spasojević-Kalimanovska, Vesna; Jelić-Ivanović, Zorana

(Elsevier Ireland Ltd, Clare, 2018)

TY  - CONF
AU  - Sopić, Miron
AU  - Mihajlović, Marija
AU  - Ninić, Ana
AU  - Bogavac-Stanojević, Nataša
AU  - Stepanović, Željka
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Janać, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Jelić-Ivanović, Zorana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3074
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Adipor1 polymorphism g.202940846g > c (rs7539542) is associated with higher cardiovascular risk in middle-aged population
VL  - 275
SP  - e248
EP  - e248
DO  - 10.1016/j.atherosclerosis.2018.06.788
ER  - 
@conference{
author = "Sopić, Miron and Mihajlović, Marija and Ninić, Ana and Bogavac-Stanojević, Nataša and Stepanović, Željka and Vekić, Jelena and Zeljković, Aleksandra and Janać, Jelena and Spasojević-Kalimanovska, Vesna and Jelić-Ivanović, Zorana",
year = "2018",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Adipor1 polymorphism g.202940846g > c (rs7539542) is associated with higher cardiovascular risk in middle-aged population",
volume = "275",
pages = "e248-e248",
doi = "10.1016/j.atherosclerosis.2018.06.788"
}
Sopić, M., Mihajlović, M., Ninić, A., Bogavac-Stanojević, N., Stepanović, Ž., Vekić, J., Zeljković, A., Janać, J., Spasojević-Kalimanovska, V.,& Jelić-Ivanović, Z.. (2018). Adipor1 polymorphism g.202940846g > c (rs7539542) is associated with higher cardiovascular risk in middle-aged population. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 275, e248-e248.
https://doi.org/10.1016/j.atherosclerosis.2018.06.788
Sopić M, Mihajlović M, Ninić A, Bogavac-Stanojević N, Stepanović Ž, Vekić J, Zeljković A, Janać J, Spasojević-Kalimanovska V, Jelić-Ivanović Z. Adipor1 polymorphism g.202940846g > c (rs7539542) is associated with higher cardiovascular risk in middle-aged population. in Atherosclerosis. 2018;275:e248-e248.
doi:10.1016/j.atherosclerosis.2018.06.788 .
Sopić, Miron, Mihajlović, Marija, Ninić, Ana, Bogavac-Stanojević, Nataša, Stepanović, Željka, Vekić, Jelena, Zeljković, Aleksandra, Janać, Jelena, Spasojević-Kalimanovska, Vesna, Jelić-Ivanović, Zorana, "Adipor1 polymorphism g.202940846g > c (rs7539542) is associated with higher cardiovascular risk in middle-aged population" in Atherosclerosis, 275 (2018):e248-e248,
https://doi.org/10.1016/j.atherosclerosis.2018.06.788 . .

Pro-oxidants and antioxidants in retinopathy of prematurity [Pro-oksidansi i antioksidansi u prematurnoj retinopatiji]

Banjac, Lidija; Banjac, Goran; Kotur-Stevuljević, Jelena; Spasojević-Kalimanovska, Vesna; Gojković, Tamara; Bogavac-Stanojević, Nataša; Jelić-Ivanović, Zorana; Banjac, Gorica

(Sestre Milosrdnice Univ Hospital, Zagreb, 2018)

TY  - JOUR
AU  - Banjac, Lidija
AU  - Banjac, Goran
AU  - Kotur-Stevuljević, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Gojković, Tamara
AU  - Bogavac-Stanojević, Nataša
AU  - Jelić-Ivanović, Zorana
AU  - Banjac, Gorica
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3135
AB  - Premature infants are susceptible to oxidative stress that causes neonatal disease such as retinopathy of prematurity (ROP). Oxidative stress is an imbalance between the production of pro-oxidants and the ability of the body to detoxify their harmful effects by antioxidants. The proliferative phase 2 ROP occurs at around 33(rd) postmenstrual week (pmw). The purpose of our study was to evaluate the pro-oxidant/antioxidant status in preterm infants at 33rd pmw. The study included 59 premature infants. ROP was classified according to the International Classification of Retinopathy of Prematurity. Total oxidative status (TOS), total antioxidant status (TAS), malondialdehyde (MDA) and paraoxonase 1 (PON1) activity were determined spectrophotometrically. The values of the pro-oxidants TOS and MDA were significantly higher in infants with ROP as compared to infants without ROP (p lt 0.05 both). There were no significant differences in the values of TAS and PON1 between the infants with and without ROP. According to study results, TOS and MDA are good markers of oxidative stress, whereas TAS and PON1 activity are unreliable in assessing antioxidant protection.
PB  - Sestre Milosrdnice Univ Hospital, Zagreb
T2  - Acta Clinica Croatica
T1  - Pro-oxidants and antioxidants in retinopathy of prematurity [Pro-oksidansi i antioksidansi u prematurnoj retinopatiji]
VL  - 57
IS  - 3
SP  - 458
EP  - 463
DO  - 10.20471/acc.2018.57.03.08
ER  - 
@article{
author = "Banjac, Lidija and Banjac, Goran and Kotur-Stevuljević, Jelena and Spasojević-Kalimanovska, Vesna and Gojković, Tamara and Bogavac-Stanojević, Nataša and Jelić-Ivanović, Zorana and Banjac, Gorica",
year = "2018",
abstract = "Premature infants are susceptible to oxidative stress that causes neonatal disease such as retinopathy of prematurity (ROP). Oxidative stress is an imbalance between the production of pro-oxidants and the ability of the body to detoxify their harmful effects by antioxidants. The proliferative phase 2 ROP occurs at around 33(rd) postmenstrual week (pmw). The purpose of our study was to evaluate the pro-oxidant/antioxidant status in preterm infants at 33rd pmw. The study included 59 premature infants. ROP was classified according to the International Classification of Retinopathy of Prematurity. Total oxidative status (TOS), total antioxidant status (TAS), malondialdehyde (MDA) and paraoxonase 1 (PON1) activity were determined spectrophotometrically. The values of the pro-oxidants TOS and MDA were significantly higher in infants with ROP as compared to infants without ROP (p lt 0.05 both). There were no significant differences in the values of TAS and PON1 between the infants with and without ROP. According to study results, TOS and MDA are good markers of oxidative stress, whereas TAS and PON1 activity are unreliable in assessing antioxidant protection.",
publisher = "Sestre Milosrdnice Univ Hospital, Zagreb",
journal = "Acta Clinica Croatica",
title = "Pro-oxidants and antioxidants in retinopathy of prematurity [Pro-oksidansi i antioksidansi u prematurnoj retinopatiji]",
volume = "57",
number = "3",
pages = "458-463",
doi = "10.20471/acc.2018.57.03.08"
}
Banjac, L., Banjac, G., Kotur-Stevuljević, J., Spasojević-Kalimanovska, V., Gojković, T., Bogavac-Stanojević, N., Jelić-Ivanović, Z.,& Banjac, G.. (2018). Pro-oxidants and antioxidants in retinopathy of prematurity [Pro-oksidansi i antioksidansi u prematurnoj retinopatiji]. in Acta Clinica Croatica
Sestre Milosrdnice Univ Hospital, Zagreb., 57(3), 458-463.
https://doi.org/10.20471/acc.2018.57.03.08
Banjac L, Banjac G, Kotur-Stevuljević J, Spasojević-Kalimanovska V, Gojković T, Bogavac-Stanojević N, Jelić-Ivanović Z, Banjac G. Pro-oxidants and antioxidants in retinopathy of prematurity [Pro-oksidansi i antioksidansi u prematurnoj retinopatiji]. in Acta Clinica Croatica. 2018;57(3):458-463.
doi:10.20471/acc.2018.57.03.08 .
Banjac, Lidija, Banjac, Goran, Kotur-Stevuljević, Jelena, Spasojević-Kalimanovska, Vesna, Gojković, Tamara, Bogavac-Stanojević, Nataša, Jelić-Ivanović, Zorana, Banjac, Gorica, "Pro-oxidants and antioxidants in retinopathy of prematurity [Pro-oksidansi i antioksidansi u prematurnoj retinopatiji]" in Acta Clinica Croatica, 57, no. 3 (2018):458-463,
https://doi.org/10.20471/acc.2018.57.03.08 . .
22
11
22

Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease

Miljković, Milica; Stefanović, Aleksandra; Simić-Ogrizović, Sanja; Vekić, Jelena; Bogavac-Stanojević, Nataša; Cerne, Darko; Kocbek, Petra; Marc, Janja; Jelić-Ivanović, Zorana; Spasojević-Kalimanovska, Vesna; Kotur-Stevuljević, Jelena

(Sage Publications Inc, Thousand Oaks, 2018)

TY  - JOUR
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Simić-Ogrizović, Sanja
AU  - Vekić, Jelena
AU  - Bogavac-Stanojević, Nataša
AU  - Cerne, Darko
AU  - Kocbek, Petra
AU  - Marc, Janja
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kotur-Stevuljević, Jelena
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3085
AB  - Some cardiovascular complications in patients with chronic kidney disease and end-stage renal disease may be caused by structurally and functionally modified lipoproteins. Redox status (advanced oxidation protein products [AOPPs]), prooxidant-antioxidant balance, total protein sulfhydryl (SH-groups), and paraoxonase 1 (PON1) activity were assessed in 77 renal patients and 20 controls. Lipoproteins were isolated using ultracentrifugation. PON1, PON3, and pentraxin-3 concentration were determined by enzyme-linked immunosorbent assay (ELISA). Dyslipidemia-Oxy-Inflammation (DOI) score was calculated as a sum of dyslipidemia, oxidative stress, and inflammation scores. The dyslipidemia score (P  lt  .001), oxy score (P  lt  .01), inflammation score (P  lt  .001), and the DOI score (P  lt  .001) were higher in patient groups compared with controls. The very-low-density lipoprotein (VLDL) fraction contained the highest amount of AOPP (P  lt  .001) compared with other lipoprotein fractions in all groups. The low-density lipoprotein (LDL) fraction contained elevated AOPP in all groups compared with the high-density lipoprotein (HDL) fraction (P  lt  .001). Significant positive correlation was observed between AOPP in LDL fraction and DOI score (rho = 0.510, P  lt  .01). Dyslipidemia, oxidative stress, and inflammation play an interactive role in renal disease and are mutually associated with redox status in VLDL, LDL, and HDL lipoproteins in plasma of renal patients.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Angiology
T1  - Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease
VL  - 69
IS  - 10
SP  - 861
EP  - 870
DO  - 10.1177/0003319718780041
ER  - 
@article{
author = "Miljković, Milica and Stefanović, Aleksandra and Simić-Ogrizović, Sanja and Vekić, Jelena and Bogavac-Stanojević, Nataša and Cerne, Darko and Kocbek, Petra and Marc, Janja and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Kotur-Stevuljević, Jelena",
year = "2018",
abstract = "Some cardiovascular complications in patients with chronic kidney disease and end-stage renal disease may be caused by structurally and functionally modified lipoproteins. Redox status (advanced oxidation protein products [AOPPs]), prooxidant-antioxidant balance, total protein sulfhydryl (SH-groups), and paraoxonase 1 (PON1) activity were assessed in 77 renal patients and 20 controls. Lipoproteins were isolated using ultracentrifugation. PON1, PON3, and pentraxin-3 concentration were determined by enzyme-linked immunosorbent assay (ELISA). Dyslipidemia-Oxy-Inflammation (DOI) score was calculated as a sum of dyslipidemia, oxidative stress, and inflammation scores. The dyslipidemia score (P  lt  .001), oxy score (P  lt  .01), inflammation score (P  lt  .001), and the DOI score (P  lt  .001) were higher in patient groups compared with controls. The very-low-density lipoprotein (VLDL) fraction contained the highest amount of AOPP (P  lt  .001) compared with other lipoprotein fractions in all groups. The low-density lipoprotein (LDL) fraction contained elevated AOPP in all groups compared with the high-density lipoprotein (HDL) fraction (P  lt  .001). Significant positive correlation was observed between AOPP in LDL fraction and DOI score (rho = 0.510, P  lt  .01). Dyslipidemia, oxidative stress, and inflammation play an interactive role in renal disease and are mutually associated with redox status in VLDL, LDL, and HDL lipoproteins in plasma of renal patients.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Angiology",
title = "Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease",
volume = "69",
number = "10",
pages = "861-870",
doi = "10.1177/0003319718780041"
}
Miljković, M., Stefanović, A., Simić-Ogrizović, S., Vekić, J., Bogavac-Stanojević, N., Cerne, D., Kocbek, P., Marc, J., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V.,& Kotur-Stevuljević, J.. (2018). Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease. in Angiology
Sage Publications Inc, Thousand Oaks., 69(10), 861-870.
https://doi.org/10.1177/0003319718780041
Miljković M, Stefanović A, Simić-Ogrizović S, Vekić J, Bogavac-Stanojević N, Cerne D, Kocbek P, Marc J, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Kotur-Stevuljević J. Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease. in Angiology. 2018;69(10):861-870.
doi:10.1177/0003319718780041 .
Miljković, Milica, Stefanović, Aleksandra, Simić-Ogrizović, Sanja, Vekić, Jelena, Bogavac-Stanojević, Nataša, Cerne, Darko, Kocbek, Petra, Marc, Janja, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Kotur-Stevuljević, Jelena, "Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease" in Angiology, 69, no. 10 (2018):861-870,
https://doi.org/10.1177/0003319718780041 . .
27
13
26

Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease

Miljković, Milica; Stefanović, Aleksandra; Vekić, Jelena; Zeljković, Aleksandra; Gojković, Tamara; Simić-Ogrizović, Sanja; Bogavac-Stanojević, Nataša; Cerne, Darko; Ilić, Jasmina; Stefanović, Ivan; Jelić-Ivanović, Zorana; Spasojević-Kalimanovska, Vesna; Kotur-Stevuljević, Jelena

(Pergamon-Elsevier Science Ltd, Oxford, 2018)

TY  - JOUR
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Gojković, Tamara
AU  - Simić-Ogrizović, Sanja
AU  - Bogavac-Stanojević, Nataša
AU  - Cerne, Darko
AU  - Ilić, Jasmina
AU  - Stefanović, Ivan
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kotur-Stevuljević, Jelena
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3067
AB  - Introduction: Cardiovascular complications, as the main cause of mortality in renal patients, are followed with altered lipoproteins composition. Considering that paraoxonase-1 (PON1) is an anti-oxidative enzyme located mainly on HDL particles, the current study has aim to investigate whether failure of kidney function leads to changes in the distribution of PON1 activity between different HDL subclasses. Materials and methods: In 77 renal patients (21 chronic kidney disease (CKD) and 56 end stage renal disease (ESRD) patients on dialysis) and 20 healthy subjects PON1 activity on HDL2 and HDL3 subclasses was determined by zymogram method that combines gradient gel electrophoresis separation of HDL subclasses and measurement of PON1 activity in the same gel. Results: Serum paraoxonase (p  lt  0.01) and arylesterase activity (p  lt  0.001) of PON1 as well as its concentration (p  lt  0.01) were significantly lower in CKD and ESRD patients compared to controls. Relative proportion of HDL3 subclasses was higher in ESRD patients than in healthy participants, while HDL2 subclasses was significantly decreased in CKD (p  lt  0.05) and ESRD (p  lt  0.001) patients, as compared to controls. Furthermore, control subjects had higher PON1 activity on HDL2 (CKD and ESRD patients p  lt  0.001) and HDL3 (CKD p  lt  0.05; ESRD patients p  lt  0.001) subclasses in comparison with the both patients groups. Also, significant negative correlation was found between paraoxonase activity of PON1 in serum and creatinine concentration (rho = -0.373, p  lt  0.01). Conclusions: This study showed that altered HDL subclasses distribution, changed PON1 activities on different HDL subclasses as well as diminished anti-oxidative protection could be important factors in atherosclerosis development in CKD and ESRD patients.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Clinical Biochemistry
T1  - Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease
VL  - 60
SP  - 52
EP  - 58
DO  - 10.1016/j.clinbiochem.2018.08.006
ER  - 
@article{
author = "Miljković, Milica and Stefanović, Aleksandra and Vekić, Jelena and Zeljković, Aleksandra and Gojković, Tamara and Simić-Ogrizović, Sanja and Bogavac-Stanojević, Nataša and Cerne, Darko and Ilić, Jasmina and Stefanović, Ivan and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Kotur-Stevuljević, Jelena",
year = "2018",
abstract = "Introduction: Cardiovascular complications, as the main cause of mortality in renal patients, are followed with altered lipoproteins composition. Considering that paraoxonase-1 (PON1) is an anti-oxidative enzyme located mainly on HDL particles, the current study has aim to investigate whether failure of kidney function leads to changes in the distribution of PON1 activity between different HDL subclasses. Materials and methods: In 77 renal patients (21 chronic kidney disease (CKD) and 56 end stage renal disease (ESRD) patients on dialysis) and 20 healthy subjects PON1 activity on HDL2 and HDL3 subclasses was determined by zymogram method that combines gradient gel electrophoresis separation of HDL subclasses and measurement of PON1 activity in the same gel. Results: Serum paraoxonase (p  lt  0.01) and arylesterase activity (p  lt  0.001) of PON1 as well as its concentration (p  lt  0.01) were significantly lower in CKD and ESRD patients compared to controls. Relative proportion of HDL3 subclasses was higher in ESRD patients than in healthy participants, while HDL2 subclasses was significantly decreased in CKD (p  lt  0.05) and ESRD (p  lt  0.001) patients, as compared to controls. Furthermore, control subjects had higher PON1 activity on HDL2 (CKD and ESRD patients p  lt  0.001) and HDL3 (CKD p  lt  0.05; ESRD patients p  lt  0.001) subclasses in comparison with the both patients groups. Also, significant negative correlation was found between paraoxonase activity of PON1 in serum and creatinine concentration (rho = -0.373, p  lt  0.01). Conclusions: This study showed that altered HDL subclasses distribution, changed PON1 activities on different HDL subclasses as well as diminished anti-oxidative protection could be important factors in atherosclerosis development in CKD and ESRD patients.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Clinical Biochemistry",
title = "Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease",
volume = "60",
pages = "52-58",
doi = "10.1016/j.clinbiochem.2018.08.006"
}
Miljković, M., Stefanović, A., Vekić, J., Zeljković, A., Gojković, T., Simić-Ogrizović, S., Bogavac-Stanojević, N., Cerne, D., Ilić, J., Stefanović, I., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V.,& Kotur-Stevuljević, J.. (2018). Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. in Clinical Biochemistry
Pergamon-Elsevier Science Ltd, Oxford., 60, 52-58.
https://doi.org/10.1016/j.clinbiochem.2018.08.006
Miljković M, Stefanović A, Vekić J, Zeljković A, Gojković T, Simić-Ogrizović S, Bogavac-Stanojević N, Cerne D, Ilić J, Stefanović I, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Kotur-Stevuljević J. Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. in Clinical Biochemistry. 2018;60:52-58.
doi:10.1016/j.clinbiochem.2018.08.006 .
Miljković, Milica, Stefanović, Aleksandra, Vekić, Jelena, Zeljković, Aleksandra, Gojković, Tamara, Simić-Ogrizović, Sanja, Bogavac-Stanojević, Nataša, Cerne, Darko, Ilić, Jasmina, Stefanović, Ivan, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Kotur-Stevuljević, Jelena, "Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease" in Clinical Biochemistry, 60 (2018):52-58,
https://doi.org/10.1016/j.clinbiochem.2018.08.006 . .
26
14
25

Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease

Munjas, Jelena; Sopić, Miron; Spasojević-Kalimanovska, Vesna; Bogavac-Stanojević, Nataša; Simić-Ogrizović, Sanja; Kravljaca, Milica; Jelić-Ivanović, Zorana

(Elsevier Ireland Ltd, Clare, 2017)

TY  - CONF
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Spasojević-Kalimanovska, Vesna
AU  - Bogavac-Stanojević, Nataša
AU  - Simić-Ogrizović, Sanja
AU  - Kravljaca, Milica
AU  - Jelić-Ivanović, Zorana
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2927
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease
VL  - 263
SP  - e198
EP  - e198
DO  - 10.1016/j.atherosclerosis.2017.06.636
ER  - 
@conference{
author = "Munjas, Jelena and Sopić, Miron and Spasojević-Kalimanovska, Vesna and Bogavac-Stanojević, Nataša and Simić-Ogrizović, Sanja and Kravljaca, Milica and Jelić-Ivanović, Zorana",
year = "2017",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease",
volume = "263",
pages = "e198-e198",
doi = "10.1016/j.atherosclerosis.2017.06.636"
}
Munjas, J., Sopić, M., Spasojević-Kalimanovska, V., Bogavac-Stanojević, N., Simić-Ogrizović, S., Kravljaca, M.,& Jelić-Ivanović, Z.. (2017). Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 263, e198-e198.
https://doi.org/10.1016/j.atherosclerosis.2017.06.636
Munjas J, Sopić M, Spasojević-Kalimanovska V, Bogavac-Stanojević N, Simić-Ogrizović S, Kravljaca M, Jelić-Ivanović Z. Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease. in Atherosclerosis. 2017;263:e198-e198.
doi:10.1016/j.atherosclerosis.2017.06.636 .
Munjas, Jelena, Sopić, Miron, Spasojević-Kalimanovska, Vesna, Bogavac-Stanojević, Nataša, Simić-Ogrizović, Sanja, Kravljaca, Milica, Jelić-Ivanović, Zorana, "Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease" in Atherosclerosis, 263 (2017):e198-e198,
https://doi.org/10.1016/j.atherosclerosis.2017.06.636 . .